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ABSTRACT 
 
Cytochrome P450 enzymes constitute a superfamily of enzyme proteins which have a 
significant part in the biotransformation of drugs and xenobiotics. Cytochrome P450s 
metabolize majority of currently known pharmaceutical agents and can cause drug-drug-
interactions with co-administered drugs as well as unwanted adverse side effects. 
Following from this, cytochrome P450s represent a challenge for successful drug discovery 
and development. By exploring ADMET properties (absorption, distribution, metabolism, 
excretion, toxicity) of a potential drug candidate in the early phases of drug discovery 
process, predictions can be made concerning the pharmacokinetics and potential drug-
drug-interactions of a drug molecule. As such, late-stage attrition of pharmaceutical agents 
can be reduced. Computational approach represents a powerful tool in predicting the 
ADMET profile of a potential drug molecule. It has the benefit over in vitro assays to 
possess less urgency for investments needed in resources, time and technology. The 
accurate prediction of the in vivo pharmacokinetics of a potential new drug, whilst existing 
merely as a virtual structure, is the ultimate goal of in silico ADMET screenings. If the 
prediction power of in silico models before chemical synthesis and expensive clinical trials 
becomes accurate and sophisticated enough, the models can replace some of the in vitro 
assays and in vivo experiments in the future and  a great deal of time, money and resources 
can be saved. Consequently, computational approach is a widely accepted tool in early 
phases of drug discovery and an area of growing interest in drug research and 
development. The purpose of this literature review is to give the reader a comprehensive 
cross-section of different in silico approaches applied in cytochrome P450 predictions. 
 
In the experimental part of this thesis, a database of 49 ligands was docked in the active 
site of CYP2B6 homology model. Based on conformations of ligands gained from 
molecular docking, comparative molecular field analysis (CoMFA) was performed by 
correlating the structural features of the ligands with experimentally determined inhibition 
potencies. Preliminary CoMFA model was generated for training set of 23 ligands and 
represented statistical values of good quality (q
2
 = 0.564, Spress =  0.523, r
2
 = 0.822, s = 
0.345). Using the preliminary CoMFA model inhibition potencies were predicted for test 
set of 26 ligands (r
2
 = 0.787, s = 0.712). Statistical values for CoMFA can be considered of 
good quality but further examining of the results is needed before the model could be 
successfully used in predicting potential substrates for CYP2B6. 
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TIIVISTELMÄ 
 
Sytokromi P450-entsyymit eli CYP-entsyymit (cytochrome P450) ovat tärkein 
vierasaineita ja lääkeaineita metaboloiva entsyymiryhmä. CYP-entsyymien kautta 
metaboloituu suurin osa nykyään tunnetuista lääkeaineista, mikä aiheuttaa ei-toivottuja 
haittavaikutuksia johtuen lääkeaineiden farmakokineettisestä profiilista ja kliinisesti 
merkittäviä yhteisvaikutuksia annosteltaessa samanaikaisesti lääkeaineita, jotka käyttävät 
samoja, CYP-entsyymien katalysoimia metaboliareittejä. Mikäli jo lääkeaineiden tutkimus- 
ja kehitystyön aikaisissa vaiheissa pystytään tunnistamaan potentiaaliset CYP-entsyymien 
substraatit ja ennustamaan potentiaalisten lääkeainemolekyylien ADMET-ominaisuudet 
(absorption, distribution, metabolism, excretion, toxicity), vältytään tilanteelta, jossa kalliin 
ja aikaa vievän tutkimus- ja kehitystyön viimeisissä vaiheissa lääkeainemolekyyli 
joudutaan hylkäämään tai jo markkinoilla oleva lääkeaine joudutaan vetämään pois  sen 
aiheuttamien yhteis- ja/tai haittavaikutusten takia. Tästä johtuen CYP-entsyymit ovat 
erittäin merkittävä ja haastava kohde uusien lääkeaineiden tutkimus- ja kehittämistyössä.  
 
Yksi tärkeimmistä työkaluista, joilla potentiaalisten lääkeaineiden ADMET-ominaisuuksia 
tutkitaan, on tietokonepohjainen lääkeaineen suunnittelu. Tietokonemallien avulla 
lääkeainemolekyyliä ja sen ominaisuuksia voidaan tutkia virtuaalisesti ja niiden 
farmakokineettinen profiili in vivo voidaan ennustaa onnistuneiden in silico-mallien avulla. 
Verrattuna in vitro- ja in vivo- kokeisiin, tietokonepohjaisella lääkeaineen suunnittelulla 
säästetään aikaa, rahaa ja voimavaroja ennen potentiaalisen lääkeainemolekyylin synteesiä 
ja kallita, kliinisiä tutkimuksia. Tästä johtuen tietokonepohjaista lääkeaineen suunnittelua 
ja in silico-malleja käytetään laajasti lääkeaineen tutkimus- ja kehitystyön aikaisissa 
vaiheissa ja menetelmän suosio kasvaa yhä edelleen. Tämän kirjallisuuskatsauksen 
tarkoituksena on antaa lukijalle läpileikkaus erilaisista in silico-menetelmistä, joita 
käytetään tutkittaessa ja kehitettäessä uusia, CYP-entsyymien kautta metaboloituvia 
lääkeaineita. 
 
Tämän työn kokeellisessa osassa 49 rakenteellisesti erilaista molekyyliä telakoitiin 
CYP2B6-entsyymin homologimalliin. Molekyylien telakoituneiden konformaatioiden 
perusteella niille tehtiin vertaileva molekyylikenttäanalyysi, CoMFA (comparative 
molecular field analysis) ja molekyylien biologinen aktiivisuus ennustettiin niiden 
rakenteellisten ominaisuuksien perusteella. Alustava CoMFA-malli, jossa käytettiin 23 
CYP2B6-entsyymin ligandin muodostamaa testijoukkoa, kykeni onnistuneesti 
ennustamaan molekyylien IC50-arvot (q
2
 = 0.564, Spress =  0.523, r
2
 = 0.822, s = 0.345). 
Tämän seurauksena alustavaa CoMFA-mallia käytettiin ennustettaessa IC50-arvot 
testijoukon ulkopuoliselle, 26 ligandin muodostamalle joukolle (r
2
 = 0.787, s = 0.712). 
Kokeellisen osan CoMFA-analyysia voidaan pitää onnistuneena ja tuloksia tilastollisesti 
merkittävinä, mutta jatkotutkimuksia tarvitaan ennen kuin luotua CoMFA-mallia voidaan 
käyttää uusien, CYP2B6-substraattien ennustamiseen. 
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ABBREVIATIONS 
 
3D  three-dimensional 
4-CPI  4-(4-chlorophenyl)-imidazole 
7-EFC  7-ethoxy-4-trifluoromethylcoumarin 
7-MFC  7-methoxy-4-trifluoromethylcoumarin 
ADMET  absorption, distribution, metabolism, excretion and toxicity 
Ala  alanine  
AM1  Austin Model 1 
ANN  artificial neural networks 
Arg  Arginine 
BIF  bifonazole 
BLAST  Basic Local Alignment Search Tool 
BNN  Bayesian neural networks 
CART  classification and regression trees 
CBS  common structural blocks 
CC  combinatorial chemistry 
CO  Carbon monoxide 
CoMFA  Comparative Molecular Field Analysis 
CPA  cyclophosphamide  
CPU  central processing unit 
CYP  Cytochrome P450 
Cα  protein backbone carbon atom 
DA  discriminant analysis  
DFT  density function theory 
FEP  free energy perturbation 
GA  genetic algorithm 
HTS  high throughput screening 
Ic50  the concentration of an inhibitory ligand which is required for 
50%   inhibition of its target 
IFA  ifosfamide 
Ile  isoleucine 
IUPAC  International Union of Pure and Applied Chemistry  
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Ki inhibitory constant; dissociation constant for an inhibitory 
ligand 
kJ  kilojoule 
Km  Michaelis-Menten constant;the substrate concentration at which 
  the rate of an enzymatic reaction is half its maximum  
KNN  Kohonen neural networks 
LD25 indicator of lethality; a dose at which 25 % of test subjects will 
die 
Leu  leucine 
LFER  Linear Free Energy Relationships 
logP logarithm of the partition coefficient of the compound between 
1-octanol and water 
MC  Monte Carlo conformational search method 
MD  molecular dynamics 
MDMA  3,4-methylenedioxy-N-methylamphetamine  
MEP  molecular electrostatic potential 
MLR  multiple linear regression 
MM  molecular mechanics 
mRNA  messenger ribonucleic acid 
NADH  reduced nicotinamide-adenine dinucleotide 
NADPH  reduced nicotinamide-adenine dinucleotide phosphate 
NNK  4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
P450BM-3  bacterial cytochrome P450; CYP102 
P450cam  bacterial cytochrome P450; CYP101 
P450terp  bacterial cytochrome P450; CYP108 
PAH  polycyclic aromatic hydrocarbon 
PCA   principal component analysis 
PCR   principal component regression 
PDB  Protein Data Bank 
Phe  phenylalanine 
pIC50  reverse logarithmic representation of Ic50 
pKa  acid dissociation constant 
PLS  partial least squares 
PM3  Parameterized Model 3 
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Q
2  
cross-validated squared correlation coefficient 
QM  quantum mechanics 
QSAR  quantitative structure-activity relationship 
r
2  
squared correlation coefficient 
RMSD  root mean square deviation 
RP  recursive partitioning 
RP73401  3-cyclopentyloxy-N-(3,5-dichloro-4-pyridyl)-4-methoxybenza
  mide 
SCR  structurally conserved region 
SDEP  standard deviation of error of prediction 
SEP  standard error of prediction 
Ser  serine 
SOM  Kohonen self-organizing map 
Spress  standard error of prediction 
SRS  substrate recognition site 
SVM   support vector machine 
SVR  structurally variable region 
Thr  threonine 
Val  valine 
X-ray  Röntgen rays 
Å  Ångström, 10
-10
 m 
ΔG  free energy of binding 
ΔH  enthalpy 
ΔS  entropy
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1    INTRODUCTION 
1.1   Cytochrome P450 Superfamily 
 
Cytochrome P450 proteins are one of the largest superfamilies of enzyme proteins (Werck-
Reichhart and Feyereisen 2000). They were first discovered in the 1950´s–60´s with 
simultaneous discovery of atmospheric oxygen incorporating in substrate molecule during 
metabolism catalyzed by metalloprotein enzymes, which eventually lead to understanding 
cytochromes having a part in oxidative metabolism (Estabrook 2003). 
  
Cytochrome P450 family is named by unique absorption peak at 450 nm with carbon 
monoxide-bound pigment, which was first found by Klingenberg in 1958 and later 
reported by Sato and Omura in 1962 (Omura 1999, Estabrook 2003). The absorption peak 
of reduced P450 is still used for the estimation of the P450 content of a probe (Bernhardt 
2006).  P stands for pigment and 450 refers the maximum absorbance at 450 nm. 
Cytochrome stands for hemoprotein and in general, cytochromes are considered as heme-
containing membrane-bound proteins with covalently bound sulfur from a cysteine residue 
as a proximal ligand (Lewis 2006).  The protein family is commonly referred as CYPs, 
shorthand for cytochrome P450s. 
 
In 1965, during research of induction of drug-metabolizing enzymes present in 
endoplasmic reticulum of liver, Remmer observed an increase in the concentration of the 
CO-binding pigment of liver microsomes during induction (Estabrook 2003). This 
triggered several studies with cytochrome P450 having the key role in many reactions of 
drug and xenobiotic metabolism.  
 
Nowadays CYPs are known to participate in biotransformation of drugs and bioconversion 
of xenobiotics, activation and metabolism of chemical carcinogens, degradation of 
herbicides and insecticides and biosynthesis of physiologically important compounds such 
as steroid hormones and vitamins (Omura 1999, Guengerich 2001a, Bernhardt 2006).  In 
total of over 700 different CYP families have been found and the number of known genes 
encoding CYP proteins is over 6000 (Nelson 2006). The number is still increasing due to 
genome sequencing started in the 90´s (Denisov et al 2005).  
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CYPs are found both in mammalian tissues and plants and they are also present in fungi 
and bacteria (Omura 1999, Werck-Reinhardt and Feyereisen 2000, Denisov et al 2005). In 
mammalian tissues the majority of CYPs are present in the liver, but they are also located 
in extrahepatic tissues, for example in the lungs and on the skin (Guengerich 2001a). CYPs 
are said to have a post at the gates of the system throughout xenobiotics enter it (Raunio 
2001). Accordingly, their role in biotransformation of drugs and xenobiotics makes CYPs 
one of the most important proteins in the field of modern drug development. However, 
only a relatively small set of cytochrome P450s contribute to drug metabolism although 90 
% of the phase I metabolism of pharmaceutical agents is mediated by them (Lewis and 
Dicking 2002, Arimoto 2006, Lewis et al 2006). From the known CYP isoforms 
subfamilies 1A, 1B, 2A, 2B, 2C, 2D, 2E and 3A are known to be involved in drug 
metabolism (Guengerich 2001b, Li 2001, Bathelt et al 2002, Lewis and Dicking 2002, 
Lewis et al 2006). Figure 1 represents the most important isoforms participating in the 
biotransformation of pharmaceutical agents. Nonetheless, in literature there are differences 
in stating which ones of the cytochrome P450 isoforms have the greatest impact on drug 
metabolism. 
 
 
In the following, only the most important CYP isoforms are presented. Introducing each 
individual CYP is beyond the scope of this research, and for further information 
concerning other isoforms the reader is referred to the literature. The CYP3A family 
comprises up to 30 % of the total hepatic content (Danielson 2002). One member of the 
family, CYP3A4 is supposed to metabolize nearly 60 % of all the known pharmaceuticals 
covering a broad variety of drugs, such as macrolide antibiotics, sedatives and immune 
 
 
 
CYP3A4/5 
~ 30 % 
CYP2C8/
9/ 18 
~ 20 % 
CYP 
2E1 
~ 10% 
CYP 
1B1 
~ 1 % 
 
 
CYP2
D6 
< 5 % 
 
CYP1A2 
~15 % 
 
CYP2C
19 
<  5% 
 
 
CYP2A
6 
~ 5 % 
CYP2
A6 
< 5 % 
CYP 
2B6 
~ 1 % 
 
Figure 1: Chart representing the most important cytochrome P450 isoforms and their 
percentage of the total hepatic content. Adapted, constructed and compiled from Rendic 
and di Carlo (1997), Pelkonen and Raunio (1998), Lin and Lu (2001) and Danielson 
(2002) 
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system modulators. In consequence, the CYP3 family and especially CYP3A4 is 
considered the most important isoform among cytochrome P450s. However, the CYP3 
family consists of only four functional genes (CYP3A4, CYP3A5, CYP3A7, CYP3A43) 
compared to e.g. the CYP2 family, which comprises of 13 subfamilies consisting of 16 
functional genes and 13 confirmed pseudogenes. As such, CYP2 family can be 
contemplated the largest family of cytochrome P450s comprising one third of the 
cytochrome P450s sequence. In addition, the total hepatic content of the CYP2 family 
enzymes is greater than the hepatic content of CYP3 family, comprising approximately 40 
% (Rendic and di Carlo 1997, Danielson 2002). Furthermore, the polymorphism of CYP2 
makes their research and discovery more difficult and time-consuming, and little is known 
of its inductive nature or transcriptional properties, albeit its participation in the 
metabolism of anti-cancer drugs (taxol, cyclofosfamide, ifosfamide), anticoagulant 
warfarin and pharmaceuticals used in Parkinson's disease (selegiline) is stated as. Since 
CYP2 family is not yet mapped through and through – as is not any other isoform –, the 
proposition of which isoform is truly the most important among cytochrome P450s, should 
weigh up carefully. 
 
As mentioned before, CYPs have a significant part in oxidative metabolism. They are 
monooxygenases, and their primary catalytic function is the transfer of one oxygen atom 
from molecular oxygen (O2) into various substrates (Bernhardt 2006). The general cycle is 
presented in Figure 2 (adapted from Guengerich 2001b). The reaction is considered to be a 
catalytic cycle which contains steps involving activation of oxygen molecule, substrate 
oxidation and product release. During this process, external reducing equivalents from 
NADPH (reduced nicotinamide-adenine dinucleotide phosphate) or NADH (reduced 
nicotinamide-adenine dinucleotide) are required (Bernhardt 2006). The reaction takes place 
after substrate binding to the active site of the CYP 450. The general formula of the 
reaction is: 
 
RH + O2 + NAD (P)H + H
+
 → ROH + H2O + NAD(P)
+ 
 
The cyclic oxidation reaction can be explained simplified as follows (Omura 1999, Raunio 
2001, Denisov et 2005, Bernhardt 2006): After substrate binding, the first electron from 
NAD(P)H is transferred to heme-bound- Fe
3+. 
Molecular oxygen, O2 binds to reduced 
heme-bound iron and forms an oxygenated complex, heme-Fe
2+
-O2. A second electron is 
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then transferred to the oxygenated complex, forming a substrate-bound heme-Fe
2+
-O2
-
,
 
which after protonation (2 H
+
) degrades into substrate-bound Fe
3+
O and a water molecule, 
H2O.  Substrate-bound Fe
3+
O is further degraded leading into an oxidized substrate and 
original Fe
3+
-P450-form. However, the reaction cycle can be explained in another way, 
which differs from the previously described by containing the one-electron transfer only 
once. The one-electron transfer from NAD(P)H occurs into substrate-bound heme-Fe
3+
O2-
leading into ferric peroxo state (Fe
3+
-O2
2-
), which is protonated leading first to Fe
3+
-O2H
-
 
(hydroperoxo)-form.  Second protonation then occurs to the distal oxygen atom of Fe
3+
-
O2H
-
, forming a very unstable intermediate Fe
3+
-OOH2, which is rapidly followed by 
splitting of  the O-O-bond and the release of one water molecule, H2O. The remaining 
porphyrin-metal-oxo-complex then attacks the substrate yielding oxygenated substrate and 
the original Fe
3+
-P450-form, and dissociates to let the cycle start all over again. 
 
Despite CYPs being considered mainly oxygenases, during their long period of evolution;   
3.5 billion years, CYP family has become very versatile, and it has a broad field of 
chemical activity (Rendic and di Carlo 1997). Among CYPs there are isomerases, 
reductases, dehydrases and NO-synthases and in addition to oxidation, they contribute to 
various other reactions listed in Table 1 (Guengerich 2001b, Danielson 2003, Bernhardt 
2006). The reactions mainly lead to the conversion of harmful xenobiotics less toxic by 
increasing their solubility, which is the first step in preparation of excretion (Denisov et al 
2005). However, exeptions can be found among the listed reactions.  
 
For example, CYP families CYP11, CYP17, CYP19 and CYP21 are involved in the 
biosynthesis of physiologically important steroids such as testosterone, progesterone and 
pregnenolone (Rendic and di Carlo 1997, Yamazaki and Shimada 1997, Bernhardt 2006, 
Storbeck et al 2007). CYP11, CYP17, CYP19 and CYP21 catalyze steroidogenesis mostly 
via hydroxylation reactions. Cytochrome P450s also activate non-toxic procarcinogens to 
toxic carcinogens (Rendic and di Carlo 1997). Cytochromes 1A1 and 1B1 oxidize e.g. 
enviromental chemicals such as polycyclic aromatic hydrocarbons (PAHs) (Shimada and 
Guengerich 2006). Oxidation of these compounds is the initial step in the activation of 
PAHs to carcinogenic products. Also CYP1A2, 2C9 and 3A4 participate in the activation 
of procarcinogens, although at much slower rates than CYP1A1 and 1B1 (Shimada et al 
2001). 
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Table 1: Chemical reactions catalyzed by cytochromes P450 (Guengerich 2001b, 
Danielson 2003, Bernhardt 2006) 
Reactions  
NO, NN- reduction Alkene epoxidation 
SO2-reduction Epoxide reduction 
Hydroperoxide reduction Isomerizations 
1-electron oxidation Oxidative C-C bond cleavage 
Aldehyde deformylation Alkyne oxygenation 
Coupling reactions Arene epoxidation 
Ring formation, expansion N-, S-, O-dealkylation 
Hydrolysis N-hydroxylation 
1,2-shifts N-oxidation 
Mechanism-based heme inactivation S-oxidation 
Mechanism-based protein modification Oxidative deamination 
Reductive dehalogenation Oxidative dehalogenation 
Dehydratations Dehydrogenation 
Hydrocarbon hydroxylation Steroid hydroxylation 
Aromatic hydroxylation  
 
 
 
Figure 2: General cytochrome P450 reaction cycle 
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1.2   Fail early, fail cheap – the need of early stage ADME profiling 
 
Drug discovery and development is a time-consuming and expensive process. The process 
takes up to average of 15 years, costing several hundred million dollars/euros (Yu and 
Adedoyin 2003). To avoid potential drug to be withdrawn from clinical studies or the 
market due to serious side effects, the need for lead compound to be studied in detail at 
early stage of drug development is highly important (Turpeinen et al 2006). Withdrawal of 
a compound usually occurs on clinical trials as a consequence of poor pharmacokinetic 
properties, animal toxicity or lack of efficacy (Ekins et al 2002).  Adverse human side 
effects are also one reason and by far the most public, visible and expensive cause of 
failures. Notably, some drugs are withdrawn from the market after successful clinical trials 
due to drug-drug-interactions or severe side effects. At this point a lot of resources have 
already been invested to the drug, so it is quite understandable, why in modern 
pharmaceutical industry the strategy "fail early, fail cheap" is accepted (Li 2001). An 
example of the applicability of the strategy related to expensiveness of late-stage attrition 
can be made of Bayer and the cholesterol lowering drug cerivastatin (Lipobay
®
/Baycol
®
). 
After cerivastatin first reaching the market in 1997, Bayer had to withdraw the drug from 
market in 2001 after 31 deaths of severe rhabdomyolysis in the USA (Charatan 2001). The 
average costs for a new pharmaceutical agent to get to the market are estimated to be 800-
900 million dollars/euros (Yu and Adedoyin 2003, Almarsdóttir and Traulsen 2005). In 
addition to this, Bayer faced up to approximately 5000 legal claims from patients, and the 
settlement payments ranged up to cost approximately 1.15 million dollars/euros in the end 
of March 2006 (Bayer 2006). The total amount of the costs is not yet available, since 
additional legal claims are possible to occur. The Lipobay story alone proves the “fail 
early, fail cheap”-strategy to be crucial and in its place in the field of successful drug 
design.   
 
Despite the time and effort put in the process, the attrition rate of drugs discovered is still 
76 % from target to IND (investigational new drug). 90 % of all tested compounds fail at 
the end of clinical trials (Yu and Adedoyin 2003). Majority of the unwanted adverse 
effects and drug-drug- interactions relate to measurable and to great extent predictable 
ADMET (absorption, distribution, metabolism, excretion and toxicity) properties. Arising 
from this, early consideration of ADMET properties has also become an essential tool in 
the field of successful discovery and development of new drugs and drug candidates (de 
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Graaf et al 2005a). Drug discovery as such is a multi-parameter optimization process, in 
which compounds are optimized for interaction with desired target, and to gain most 
favored drug-like properties of the candidate compounds (van de Waterbeemd and Gifford 
2003). This parallel and iterative optimization approach includes also physicochemical 
properties (lipophilicity, solubility, pKa, permeability, hydrogen bonding), selectivity, and 
potency of the compound, in addition to ADMET parameters. Since the optimization 
process on the whole is highly complex in nature, computational approach is more than 
suitable for the purpose, making the process more straight-forward, time-saving and as 
such, less expensive  compared to more conventional methods (Zlokarnik et al 2005). 
 
1.3   In vitro test systems – The traditional method in early stage drug discovery 
 
Traditionally, in vitro assays have been used during early drug development, in assessing 
the potency of a compound to become a drug by studying its ADMET properties and 
providing with reasonable accuracy a preliminary prediction of the behavior of the 
compound in vivo  (Yu and Adedoyin 2003). Over the time, in vitro assays have improved 
significantly via protocol simplification and technological advancement to keep up with 
the growing amount of information on ADMET data and the shortened cycle time 
characteristic to early drug discovery. Therefore various medium- and high-throughput in 
vitro ADMET screens using robotics and miniaturization are now available. However, the 
demand for preventing late-stage attrition by predicting ADMET properties is still 
increasing, and better results in screening the most promising compounds for further 
optimization are wanted. This creates a need for methods producing higher throughput 
with less investments which is characteristic for methods such as in silico modeling (van 
de Waterbeemd and Gifford 2003, Yu and Adedoyin 2003). 
 
1.4 In silico – A challenging approach in ADMET profiling 
 
The phrase in silico refers to an experiment or process performed virtually, as a computer 
simulation. Currently, computational tools are of great importance in modern drug 
discovery and development due to their ability to save time, resources and money and to 
produce rational and reliable information (Boobis et al 2002, Ekins 2003). 
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In silico methods are basically used in assisting in the selection of appropriate assays and 
compounds to go through the assays and further development (Boobis et al 2002). The 
benefit of using computational approaches over in vitro assays is less investment needed in 
resources, time and technology. The accurate prediction of the in vivo pharmacokinetics of 
potential new drug, whilst existing merely as a virtual structure, is the ultimate goal of in 
silico ADMET screenings. Obtaining merely virtual structures means avoidance of the 
need to synthesize and screen every molecule perused (Ekins et al 2002). If the prediction 
power of in silico models becomes accurate and sophisticated enough, the models can 
replace in vitro assays and in vivo experiments in the future (van de Waterbeemd and 
Gifford  2003). Nevertheless, at the moment best results in generating new and effective 
drugs are obtained in combination with experimental and computational approaches. 
Integration of both of these methods is valuable for generating more interpretable data, in 
order to identify the most promising compounds in drug discovery process for further 
optimization. The large databases containing information of the absorption, distribution, 
metabolism, excretion and toxicology of the compounds yielded by in vitro studies, are 
converted into more interpretable format by generating predictive computational 
algorithms, which are used to improve the process of drug discovery (Ekins 2003, 2006).  
 
Computational approaches can be roughly divided into two main categories: ligand-based 
approaches and structure-based (protein-based) approaches (Yamashita and Hashida 2004, 
de Graaf et al 2005a, de Groot 2006), which are discussed in more detail in chapters 2 and 
3 of this text. The approaches have been developed based on predicting potential substrates 
or inhibitors for target proteins, concentrating on either small molecules metabolized by 
certain protein or on the structures of proteins, and predicting ADMET properties of the 
compounds based on their chemical structure (de Groot 2006). The underlying need for 
this rests on the insufficiency of both combinatorial chemistry (CC) and high-throughput 
screening (HTS).  Although having a crucial part in lead optimization and finding potential 
candidate drugs as being faster than conventional lead discovery, CC and HTS do not 
reduce the attrition rate of new drugs enough, nor increase the number of marketed new 
drugs as expected (Norinder and Bergström 2006). More robust and accurate 
computational tools are needed in order to design new compounds and libraries with 
desirable profile (O'Brien and de Groot 2005). 
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Ligand-based approach can be considered as an empirical method using statistical tools to 
explore linear and non-linear relationships between the structural descriptors of ligands, 
and observed parameters of a particular ADMET property (Ekins et al 2002). It includes 
methods such as pharmacophore modeling, quantitative structure-activity relationship 
(QSAR), three-dimensional (3D) QSAR and similarity searches (Ekins et al 2002, 
Yamashita and Hashida 2004). QSAR-approaches are derived from physicochemical and 
topological properties of compounds, and have proved to be pragmatic, rapid and rather 
successful approach in predicting drug metabolism by CYPs (de Graaf et al 2005a). 
 
Structure-based approach endeavors to be insightful as well as predictive, including 3D 
molecular modeling techniques such as protein homology modeling and ligand-protein 
docking, as well as pharmacophore modeling based on x-ray or NMR structures of proteins 
(Ekins et al 2002, Yamashita and Hashida 2004, de Graaf et al 2005a, Wolber and Kosara 
2006). Molecular modeling provides information of the behavior of molecules and 
molecular systems and their interaction with one another, using quantum mechanical 
methods and computational chemistry. Computational chemistry combines quantum 
mechanics, molecular mechanics, minimization, simulation, conformational analysis and 
other computer-based methods providing the possibility to understand and predict the 
behavior of target system and compound (Leach 2001). This information can be further 
exploited in predicting the ADMET properties of the drug candidates. Structure-based 
approach demands more computational power than ligand-based approach, although 
having lower throughput (Ekins 2003). The best ADMET models overall are consensus 
models, combining information of several computational models tailored to work in the 
necessary context (Yamashita and Hashida 2004, O'Brien and de Groot 2005).  
 
This literature review presents computational approaches capable of producing predictive 
information concerning the target systems in the field of drug discovery and development. 
The main focus lies in in silico predictions of cytochrome P450 superfamily, considering 
both ligand- and protein-based methods. However, also in silico methods combining 
information from both of these methods are discussed. 
 
 
 
 
20 
 
2   LIGAND-BASED MODELS 
 
Ligand-based models concentrate on information gained from the ligands only. Although 
ligand-based models can produce indirect information concerning the active site of the 
target protein, the focus is on a set of known substrates, inhibitors or metabolic products, 
and on their shape, electronic and physico-chemical properties, as well as conformations. 
Computational modeling utilizes mainly ligand-based models since the crystal structures of 
proteins are not as easily available as small molecules. Ligand-based models can be 
divided into two main categories: Pharmacophore models and quantum mechanical models 
(de Graaf et al 2005a).  
 
The invention of pharmacophore per se occurred by Perkins in the middle of the nineteenth 
century, during his research concerning synthesis of coloring agents (Gund 2000). He 
discovered that the skeleton of a molecule left untouched but varying the functional 
groups, caused different colors and related properties. Near the end of the century, Paul 
Ehrlich discovered the coloring agent's ability to dye different tissues and thus, be able to 
cure certain diseases, which lead to the discovery of drugs having to bind to receptors for 
exerting their medicinal effect. This was followed by understanding the “lock and key” 
type of interactions, making way for fundamentals of pharmacophore modeling. The 
definition of pharmacophore was first offered in the early 1900s by Ehrlich, describing 
pharmacophore as a molecular framework that carries (phoros) the essential features 
responsible for a drug's (pharmacon) biological activity (Güner 2000; Erhlich 1909, Gund 
1977). It was not until almost 70 years later that the definition was updated by Peter Gund 
in 1977 to its recent form: “a set of structural features in a molecule that is recognized at a 
receptor site and is responsible for that molecule's biological activity.” Modern definition 
of pharmacophore is based on IUPAC recommendation: “A pharmacophore is the 
ensemble of steric and electronic features that is necessary to ensure the optical 
supramolecular interactions with the specific biological target and to trigger (or block) its 
biological response” (Guerin et al 2006).  
 
As Erlich discovered, in order to interaction occurring between a compound and the target 
protein, compounds have to bind to the receptor (Höltje et al 2003). Binding requires the 
compounds presenting certain structural elements of identical functionality in sterically 
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consistent locations to the target protein. For exerting qualitatively similar activities at the 
particular receptor, the compounds are assumed to possess similarity in these structural 
elements essential for the binding, producing generally similar biological properties.  
 
Pharmacophoric groups are considered as representation of similar physical and chemical 
properties of the compounds, and specified spatial relationships of the groups, usually 
expressed as distances, distance ranges and geometric measures such as angles and planes, 
(Leach 2001). Generally used pharmacophoric features include hydrogen bond donor or 
acceptor, basic, acidic, aromatic or hydrophobic atoms (Mason et al 2001). However, 
pharmacophore does not merely represent particular molecular structure or association of 
functional groups. It can be considered providing a multiple pharmacophore descriptor, 
which after analyzing internal relationships between the descriptors, results a map 
representing the essential, steric and electronic features for a group of molecules exhibiting 
optimal interaction with the target structure, and which provides a certain pharmacological 
effect (Wermuth 2006). A representation of a pharmacophore is presented in Figure 2 
(adapted from Ekins et al 1999c).  
 
 
Figure 3: Pharmacophore model for CYP3A4 
substrates. Represented are interbond angles and 
distances between pharmacophoric features. Red 
sphere represents hydrophobic region, purple 
regions are hydrogen bond acceptor features and 
green spheres are hydrogen bond donors 
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One of the major tasks using molecular modeling is to solve the pharmacophores for 
uniform groups of drug molecules. Information of the hypothetical pharmacophore for a 
group of molecules provides a very important source for understanding drug-receptor 
interactions at the same level (Höltje et al 2003). 
 
According to de Graaf and coworkers (2005a), pharmacophore models can be further 
divided into two groups: classical pharmacophore models and 3D-QSAR models, which 
are discussed in the following chapters (de Graaf et al 2005a). Both methods are based on 
empirically derived information of substrates, inhibitors and metabolic products of the 
CYPs, concerning the shape, electronic properties and conformations of the compounds. 
The information can be further applied to produce knowledge about and on the active site 
of target protein and the features essential for ligands, in order to be biologically active and 
thus, potential lead compounds in drug discovery process.  
 
Quantum mechanical (QM) models differ from pharmacophore models by focusing on 
elements of much smaller scale and consequently demanding more computer capacity due 
to complicated computational algorithms, which QM requires. Following from this, QM 
models provide more detailed information of the cytochrome P450s and their ligands. The 
QM models are discussed in chapter 2.3.  
 
2.1   Classical pharmacophore models 
 
Classical pharmacophore models are constructed by aligning the chemically similar 
structural elements essential for pharmacological activity of the molecule, pharmacophoric 
groups, onto each other (Yamashita and Hashida 2004, de Graaf et al 2005a). Molecular 
alignment can be addressed as approximating the binding geometry of a set of ligands. If 
the alignment is correct, the relevant chemical features of the ligand can be readily 
extracted in order to derive a pharmacophore, which can be used in searching for possible 
substrates or inhibitors from a ligand database (Lemmen and Lengauer 2000). As such, 
molecular alignment is the most important step concerning pharmacophore modeling in 
general, and it is discussed in detail in chapter 2.2.1. 
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Classical pharmacophore models can be applied as an input for 3D database searching of 
new substrates and inhibitors for potential drugs, molecular graphics, or automated 3D 
design and 3D-QSAR methods (Mason et al 2001). Using the information gained from the 
molecular alignment itself and the pharmacophore models, it is possible to derive 
complementary information of the structure and electrostatic distribution in the active site 
of target proteins (de Groot and Ekins 2001).  
 
Still, classical pharmacophore models give an estimation of the activity of new 
compounds, not exact information. It should be noted, that models are based on a particular 
pharmacophore model, and another pharmacophoric model can give different kind of 
predictions (de Graaf et al 2005a). Despite recent classical pharmacophore models give 
predictions of the specificity and binding of the ligands in the active site based on their 
structural features, 3D-QSAR models are more advanced in producing quantitative 
parameters concerning ligand binding affinity towards the cytochromes. 
 
Significantly, pharmacophore models can be constructed also based on available structures 
of ligand-protein complexes (Wolber and Langer 2005). In this approach, pharmacophores 
are derived based on chemical features and volume constraints of the bound ligand, as well 
as amino acids surrounding the ligand in the active site. The advantage of using ligand-
protein complexes is producing selective pharmacophore models in screening of large 
compound databases for active molecules with described binding mode.  
 
Classical pharmacophore models are quite useful when there is no structure available of 
the target enzyme (Lemmen and Lengauer 2000, Arimoto 2006). Nevertheless, they can 
also be combined with one another, when the structure of the protein is available (Griffith 
et al 2005). The combination of both models often produces more informative models of 
ligand-protein interaction. However, in most occasions protein structure of cytochromes 
P450 is not available due to complex and difficult nature of producing protein model, 
which actually works. Currently, there are few human cytochrome structures available 
(CYP2A6, CYP2B4, CYP2C5, CYP2C8, CYP2C9, CYP2D6 and CYP3A4), and the focus 
of new drug discovery is in the ligands of cytochromes (Williams et al 2000, Scott et al 
2004, Lewis et al 2006, Marechal and Sutcliffe 2006, Rowland et al 2006, Yano et al 
2006). Like Arimoto (2006) states in his article, “The ultimate goal is to predict the CYP 
specificity and the interactions for novel compound from its (ligand's) chemical structure”. 
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An overview of the vast and still growing number of pharmacophore models of 
cytochrome P450 substrates is presented in Table 2. 
 
Table 2: Summary of key ligand-based pharmacophore features of cytochrome P450 
 
CYP 
 
Key features of ligand-based pharmacophore 
  
Reference 
1A2 Inhibitor model includes hydrogen bonding , 
negative charge favored areas near nitrogen 
atom of quinoline ring, hydrophobic 
interactions between substrates and protein 
 Korhonen et al 2005 
2A5 Lactone moiety important to inhibition, 
negative charge favored near the carbonyl 
oxygen and over both sides of coumarin ring 
plane, a large steric area allowed locating 
around 7-position of coumarin 
 Poso et al 2001 
2A6 Naphthalene derivatives are potent inhibitors, 
partial negative charge increases inhibition 
potency, heterocyclic nitrogen atom decreases 
inhibition potency 
 Poso et al 2001,  
Rahnasto et al 2005 
2B6 Two possible pharmacophores generated. One 
is having hydrogen bond acceptor at a 
distance of 4.6 Å from substrates reaction site, 
the other having 4.9 Å them at distances of 3.4 
and 4.0 Å from the reaction site. Both have 
two hydrophobic regions, first one having site, 
the second having them at distances of 4.1 and 
7.8 Å. Hydrophobicity and hydrogen bonding 
crucial for ligand binding 
 Ekins et al 1999b,  
Wang and Halpert 2002 
2C8 Substrates possess long hydrophobic chain 
with acidic or polar group 12.9 +/- 0.8 Å from 
the oxidation site and hydrophobic or 
aromatic moiety 3.9 +/- 0.7 Å from the 
oxidation site. Two supplementary polar 
groups are located 4.4 +/- 0.3 Å and 8.6 +/- 0.3 
Å from the oxidation site 
 Melet et al 2004 
2C9 Hydrogen acceptor at a distance of 3.4-5.7 Å 
from hydrogen bond donor or second 
acceptor, hydrophobic feature positioned at 
3.0-5.8 Å from the first hydrogen acceptor. 
Hydrophobic region usually concludes 
aromatic ring, locating 5.6 -9.8 Å from the site 
of oxidation 
 Ekins et al 2000,  
de Groot el al 2002 
2C18/19 Substrate model includes two hydrophobic 
regions and electropositive binding sites 
 Ridderström et al 2001 
2D6 Inhibitor models consist of tertiary nitrogen 
atom, a flat hydrophobic region, a region with 
additional  
functional groups having lone-pairs The 
nitrogen atom locates at a distance of 5-7 Å 
from the site of oxidation 
 Ekins et al 2001 
25 
 
Table 2 continues    
 
CYP 
 
Key features of ligand-based pharmacophore 
  
Reference 
2E1 Substrates are usually small at size bearing 
lipophilic regions. They usually contain 
benzene ring 
 Lewis et al 2003 
3A4 Two substrate models: First one has a 
hydrogen bond acceptor at a distance of 5.5-
7.8 Å from the site of metabolism and 3 Å 
from the oxygen molecule bound to heme.  
Second model includes two hydrogen bond 
acceptors, a hydrogen bond donor and a 
hydrophobic region. Also two inhibitor 
models: One has three hydrophobes at 
distances of 5.2-8.8 Å from hydrogen acceptor, 
the other has three hydrophobes at distances 
of  4.2-7.1 from hydrogen bond acceptor, and 
further 5.2 Å from another hydrogen acceptor 
OR one hydrophobe at distances of 8.1-16.3 
from the two furthest of three 
hydrogen bond acceptors 
 Ekins et al 1999a, c, 2001 
3A5/A7 Inhibitor model consists of two aromatic rings, 
hydrogen bond acceptor and three 
hydrophobic features only a short distance 
apart 
 Ekins et al 2003 
17 (17α-
hydroxylase) 
Inhibitor model for steroids and non-steroids 
include one or two hydrogen bond acceptors 
and three hydrophobic groups. In imidazole 
moiety, the N-3 acts usually as a acceptor  
 Ahmed 1999, 
Clement et al 2003 
19 (aromatase) Inhibitor model includes hydrogen bond 
acceptor and two hydrophobic areas near C6 
of steroids 
 de Groot and Ekins 2002 
51 (14 α-
demethylase) 
Imidazoles are more potent than triazoles and 
N3 and N4 of azole ring, etheral oxygen atom 
and an aromatic ring centroid are essential. 
Inhibitor model possess a hydrogen bond 
acceptor and three hydrophobic regions 
 Ekins et al 2001 
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2.2   3D-QSAR models 
 
QSAR (quantitative structure activity relationships) is a method, which correlates 
molecular structure of a compound to some kind of in vitro or in vivo biological property, 
mostly biological activity in the field of modern drug discovery (Winkler 2002). In 
general, QSAR relates numerical properties of the molecular structure (descriptors) to its 
activity by using a mathematical model, which tries to find a correlation between the 
descriptors and activity by means of statistical methods (Leach 2001).  
 
QSAR was first developed by Hansch and Fujita in 1969, when Hansch developed 
equations correlating biological activity to electronic characteristics and hydrophobicity of 
molecules. At the beginning, the method was named Linear Free Energy Relationships 
(LFER), due to correlation occurring linearly between the biological activity, and free-
energy related physicochemical parameters such as logP (the logarithm of the partition 
coefficient of the compound between 1-octanol and water) (Debnath 2001). Hansch 
described the correlation using different equations, for example: 
 
log(1/C) = k1logP – k2(logP)
2
 + k3σ  + k4   Eq. 1 
 
In this equation, C is the concentration of the compound, required to cause a standard 
response in a given time. σ is the Hammet substituent parameter, which describes the effect 
of substituents, and k1, k2, k3 and k4 are constants. However, there are several other 
equations available describing the correlation in a different, more complicated way, 
depending on the parameters of interest. The equations can be either linear or non-linear in 
nature. There is diversity among the descriptors (calculated or measured properties) also, 
since they can be either fragment-based describing only a small section of the molecule, or 
molecular descriptors covering the whole molecule (Winkler 2002). The number of 
descriptors is enormous, covering both 2D- and 3D-descriptors subdivided in many ways 
(e.g. spatial, electronic, thermodynamic, conformational, topological and structural 
properties) (de Groot 2006). For example, Free and Wilson suggested an approach 
concerning substituents and their effect on biological activity, and Kier and Hall 
represented structural indices affecting the activity (Debnath 2001).  
 
27 
 
The multiple approaches together with Kubinyi's bilinear model (1977) have had 
considerable effect on understanding how chemical structures influence biological activity. 
Notably, the effect on activity can be generated using single parameters or a combination 
of them. With multiple parameters the data set size becomes larger and more difficult to 
interpret with linear functions, and therefore non-linear techniques such as neural networks 
are needed. Neural networks with other non-linear techniques are discussed further with 
other machine learning methods at chapter 2.2.3.  
 
The classical explanation of QSAR includes formulating the relationships between the 
structure of a molecule and its biological response. In the QSAR approaches developed by 
Hansch and Fujita, the molecular structure was represented with 2D descriptors such as 
molar refractivity, Hammet constant σ, hydrophobic constant, and with the number of 
hydrogen bond donors and acceptors (Hansch and Fujita 1964, Hansch et al 1995, Winkler 
2002). However, the interaction between a ligand and a receptor involves three-
dimensional distribution of properties, as discussed in the previous chapter. This has led to 
the development of 3D-QSAR techniques, which by far, are the most powerful 
computational tool in supporting the chemistry side of indirect drug design (Winkler 2002, 
Höltje et al 2003).  
 
The primary aim of 3D-QSAR analysis is to establish a correlation between structurally 
and biologically characterized compounds with spatial fingerprints of different field 
properties of each compound, namely steric (shape and volume), electronic (electrostatic 
potential and electric charge) and lipophilic (how polar or non-polar the sections of the 
molecule are) properties (Winkler 2002).  
 
In general, 3D-QSAR pharmacophore modeling combines the approach used in classical 
pharmacophore modeling with quantitative information gained through mathematical 
equations based on diverse sets of mathematical descriptors, encapsulating the key 
property of molecular structure (Vorpagel and Golender 2000, Martin 2002). The 
combination is obviously more informative than either of them alone since information on 
activity is not merely binary, as in the case of classical pharmacophore modeling. 
Additionally, the 3D nature of interaction between ligand and receptor is captured in a 
larger scale using essential features for activity. Based on the generated models, forecasts 
can be made of the potency of compounds not included in the derivation of preliminary 
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model. Hence, to return to the earlier chapter 1.2 in this research, the models can then be 
further used in predicting ADMET properties of drugs in silico as discussed. The potential 
of 3D-QSAR modeling to be applied in the early stages of drug discovery, makes it a 
powerful tool in preventing unwanted late stage attrition of drug candidates (de Graaf et al 
2005a). 
 
The advantage of 3D-QSAR methods lies also in its ability to cover wide ranges in 
molecular structures, as well as biological response or effect, producing as much as 
possible information regarding the active site and new lead compounds. This increases the 
statistical significance of the 3D-QSAR pharmacophore models. The predictive power of 
3D-QSAR has been proven in several studies in which the biological activities of novel 
compounds have been correctly predicted. Modeling CYP binding affinity for ligands, the 
3D-QSAR models are validated and constructed using several parameters, which directly 
or indirectly have an impact on ligand binding and affinity towards CYP enzymes, 
including Km, Ki or IC50. For further information concerning the applications discussed, the 
reader is referred to the original literature. Due to the applicability of 3D-QSAR 
techniques, several methods have emerged for generating the relationship between the 
structure of a molecule and its effect on activity. In most occasions, the method of choice 
seems to be CoMFA (comparative molecular field analysis), which will be discussed in 
more detail in chapter 2.2.2 and also in the experimental part of this text. 
 
2.2.1   Molecular alignment  
 
All 3D-QSAR models are limited by the good quality of measuments concerning them, 
which can be aggravated as "Garbage in, garbage out"- principle of QSAR models 
(Vorpagel and Golender 2000). The model can be only as good as the descriptors used, and 
the information the descriptors contain. In constructing 3D-QSAR models, as well as any 
kind of pharmacophore model, the alignment of molecules is the crucial step in 
constructing useful models (Lemmen and Lengauer 2000, Melani et al 2003).  Molecular 
alignment produces energetically favorable conformations of substrates and/or inhibitors, 
and can be conducted manually or computationally using several algorithmic methods 
(Lemmen and Lengauer 2000, de Graaf et al 2005a).  
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Manually performed alignment is feasible, when the test set is not too large but to avoid 
biased procedures and to save time, computational methods are preferred (Tervo et al 
2004, 2005). Manual alignment is conducted based on the decision, which functional 
groups or atoms to superimpose (Höltje et al 2003). In other words, it has to be determined, 
which of the structures are considered similar and crucial for activity. Selecting the 
structures to be aligned, can be conducted based on information of known, potent ligands 
and their structures. 
 
In modeling classical pharmacophores, structurally quite similar compounds are 
emphasized using atom-by-atom superposition. However, Höltje et al (2003) have stated 
that using diverse molecular structures, and aligning the molecules based on functionally 
equivalent elements or molecular fields, exhibits more informative pharmacophore models 
accommodating better e.g. the versatility of CYP substrates. With 3D-QSAR methods, 
alignment is mostly conducted on the basis of similar molecular energy fields since by 
using this method, the 3D space of the molecules is taken into more thorough consideration 
(Leach 2001, Höltje et al 2003, Rönkkö et al 2006). After all, molecular fields model 3D 
structures in space surrounding atomic nuclei, which have an impact in non-covalent 
interactions most important for biological effects occurring at molecular levels (Rönkkö et 
al 2006). Using molecular energy fields as a criterion for molecular similarity instead of 
plain molecular structure, compounds with various molecular structures can be aligned 
(Kim et al 1998, Höltje et al 2003). As such, the alignment of molecules is possible if they 
represent similar molecular field properties. Also, alignment based of molecular fields 
leads to the possibility of several alignment alternatives (Tervo et al 2004, 2005). The 
intricate nature of aligning molecules by molecular fields has set the scene for much freely 
and commercially available software concerning pharmacophore and 3D-QSAR modeling 
(Table 3).  
 
Despite the underlying method, the key building block in creating successful alignments in 
concerning both pharmacophore and 3D-QSAR models, is a good reference structure; the 
template molecule (Klebe et al 1999, de Graaf et al 2005a). Template molecule is usually 
an active ligand bearing certain prevailing qualities important to cause biological response, 
namely:  
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1) is large 
2) relatively rigid to limit conformational freedom 
3) contains essential groups 
4) is specifically metabolized by the target protein 
5) is regio- and/or stereoselectively metabolized 
 
However, molecular alignment of ligands suffers from certain limitations affecting the 
results (de Groot 2006.) All ligands are assumed to bind to the receptor at the same binding 
site and and at the same (rigid) binding mode. This is not the case with CYPs, as it is 
widely accepted that CYPs allow certain degree of conformational flexibility within both 
ligands and in the active site, causing complex binding behavior (Locuson and Wahlstrom 
2005). CYP3A4 even allows multiple ligands to bind simultaneously (Chohan et al 2006). 
Also, assuming the ligands to share a mutual low-energy conformation can be misleading, 
since the assumption leaves out for example, strained conformations in transient states of 
chemical reactions (Höltje et al 2003). By widening the energy range of ligands the 
number of accessible conformations increases dramatically, making it possible to consider 
more single conformations. 
 
Nevertheless, it should be noticed that due to different alignment algorithms based on 
different concept, the quality and reproducibility of the results can vary to great extent, 
especially when crystal structures are not available for ligand-protein complexes presenting 
the proper binding mode of active ligands (Höltje et al 2003, Melani et al 2003). One 
alignment method can be useful and predictive in some contexts, and cause problems in 
another context (Kim et al 1998). Versatility concerning the quality of the results makes it 
difficult to estimate beforehand, which alignment method actually produces the desired 
information and thus, multiple alignments are needed (Rönkkö et al 2006).  
31 
 
Table 3: Examples of computational molecular modeling software for classical 
pharmacophore and 3D-QSAR modeling used in cytochrome P450 predictions. 
 
Program 
 
Description of the research and results 
 
 
 
Reference  
CoMFA *CoMFA model for inhibitory molecules of 
CYP1A2 was generated, confirming the 
importance of hydrophobic interactions for 
inhibitory power. The model also pointed out 
hydrogen bonds and electrostatic fields in 
agreement with earlier studies.  
**CoMFA models were generated for 
inhibitory compounds of CYP2A5 and 
CYP2A6. Both models suggested negative 
charge at certain positions of a naphthalene 
ring to increase the inhibition potency of 
compounds. Additionally, steric substitution at 
position 2 of the naphthalene ring on the 
CoMFA model of CYP2A5 would increase the 
inhibition potency.  
 
 *Korhonen et al 2005, 
**Rahnasto et al 2005, 
 
Almond Alignment independent GRIND descriptors 
(GRID-independent descriptors) were 
calculated for a set of rigid and flexible 
competitive CYP2C9 inhibitors and non-
inhibitors with different molecular size. Using 
the obtained models inhibitors and non-
inhibitors were distinguished. Pharmacophore 
model for competitive inhibitors gave 
predictions in 0.5 log units of actual values for 
all but one compound. 
 
 Afzelius et al 2002 
GRID Selectivity of CYP2C8, 2C9, 2C18, 2C19 and 
amino acids determining the specificity was 
analyzed using GRID calculations. As a result 
the most important determinants were 
hydrophobicity and geometry of active site. 
Based on homology models of the CYP2 
enzymes, an inverse pharmacophore models 
was constructed, producing resembling 
interactions with a docked reference structure. 
 
 Riddeström et al 2001 
Catalyst A pharmacophore models was built for 38 
substrates of CYP3A4. The model consisted of 
two hydrogen bond acceptors, one hydrogen  
donor and one hydrophobic region, giving fast 
fit function (r) value of 0.67. The model 
predicted Km(apparent) values lower than 1 log 
unit for a test set of 12 molecules. 
 Ekins et al 1999c 
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Table 3 continues 
 
Program 
 
Description of the research and results 
 
 
 
Reference  
MS-WHIM MS-WHIM model based on statistical analyses 
of molecular descriptors for size and shape of 
16 CYP2B6 substrates was generated. The 
model gave q
2
 value of 0.607 yielding 
satisfactory predictions for a test set of 
molecules. 
 Ekins et al 1999b 
MetaSite *MetaSite was applied to a set of CYP3A4-
mediated substrates for predicting their 
metabolic sites using protein crystallographic 
structure and homology model. Predicted 
active sites agreed with experimental results in 
78% of the cases*. 
**Metabolic sites were also predicted for 
substrates of CYP1A2, 2C9, 2C19, 2D6 and 
3A4 using crystal structures and homology 
models of the CYPs. The method predicted the 
site for metabolism successfully in an average 
of 85 % of the cases**. 
 
 *Zhou et al 2006, 
**Cruciani et al 2005 
 
2.2.2   CoMFA 
 
CoMFA is considered as a starting point for the development of 3D-QSAR techniques 
(Martin 2002, Höltje et al 2003). It was invented by Cramer and coworkers (1988), which 
were the first to be able to calculate the steric and electronic properties of chemical 
structures in a 3D grid surrounding the molecules, and correlating these properties with 
variation in the biological or chemical activity by means of statistical methods.  
 
Steric potential in CoMFA is usually represented by Lennard-Jones function and 
electrostatic potential with simple Coulomb function (Cramer et al 1998, Clark et al 2000, 
Höltje et al 2003). The idea of the concept is that changes in the biological activity are 
closely related to equivalent changes in shapes and strengths of the non-covalent 
interaction fields surrounding the molecule. Relationships between the interaction fields 
and biological activity are calculated using PLS (partial least squares), which builds a 
statistical model from energy values predicting the activity. 
 
CoMFA starts with selecting a set of compounds, series design, by aiming to gain as much 
as possible information with a minimum number of compounds (Kim et al 1998, Leach 
2001, Höltje et al 2003). Basically, one has to minimize collinearity between predictor 
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properties, and maximize the variance between the properties. Activity of molecules 
should span about three log units of Ki or IC50. Also, the substituent space with smallest 
amount of compounds has to be mapped, and the geometries and optimization has to be 
accounted for.  
 
Bioactive conformation of each compound is suggested as in the beginning of classical 
pharmacophore modeling, and the compounds are superimposed onto each other (Kim et al 
1998, Leach 2001, Höltje et al 2003).  After superimposing, the interaction fields 
surrounding all the molecules are calculated. Interactions between a probe atom (usually 
sp
3
 carbon with +1 charge) and the molecule at each intersection of a grid with a chosen 
grid spacing (1-2 Å) surrounding the molecule are measured. The relationships between 
the interaction fields and biological activity are calculated using PLS, which builds a 
statistical model from energy values predicting the activity. PLS models are also validated 
to ensure the quality and predictive power of the model. Validation of the model is usually 
conducted by Leave one out cross-validation-method. This procedure calculates as many 
models as there are compounds in the data set, and then leaves each compound out of the 
model and predicts its activity. Another possibility is to use standard cross-validation, 
which divides the compounds into a specified number of groups leaving each one out, one 
at a time. After repeating this once with every molecule or molecule group, Q
2
 (cross-
validated squared correlation coefficient) and SDEP (standard deviation of error of 
prediction) are calculated for observed and predicted activities of each molecule. Equations 
for determining Q
2
 and SDEP can be found in the literature (Ekins et al 1999b, Höltje et al 
2003). Notably, the same values can be obtained from many, slightly different equations. 
 
It is possible to obtain standard error of prediction (SEP) and standard r
2
 values, in addition 
to SDEP and Q
2
. Standard r
2 
(also called R
2
)
 
represents the quality of a simple linear 
regression equation being able to adopt values between 0.0 and 1.0. The higher the value, 
the more of the variations observed can be explained by variation in independent variables. 
Standard r
2
 represent goodness of fit, whereas Q
2 
(also called cross-validated r
2
, q
2
 or R
2
cv 
values) represents the goodness of prediction. Values greater than 0.5, decrease the 
possibility of chance correlation, and indicate that the model has some predictivity. The 
higher the value, the better the model. 
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Over-fitting of the data can be observed when the SDEP value increases, after first 
decreasing for the first few latent variables (components) reaching a minimum. 
Components can be seen as a group of properties correlating with each other. The number 
of components should be carefully chosen, in which “the 5 % rule” might be helpful. If 
adding a component decreases the SDEP by less than 5 %, the simpler model with fewer 
components is preferred. Or in other words, if the Q
2
 increases by at least 5 % upon 
increasing the number of components by one, it might be justified to add an additional 
component. However, this is not always the case due to the many adjustable variables 
involved in CoMFA (Kim et al 1998). 
 
CoMFA has been successfully used in many cytochrome P450 applications, some of which 
are represented in Table 3. Several other CoMFA models are available but for clarity, only 
a few of them are representend in the table. For example, Korhonen et al (2005) created a 
CoMFA model for inhibitory molecules of CYP1A2 to gain structural information about 
the interaction between the molecules and CYP1A2 active site. 46 molecules with 
measured IC50-values were analyzed using CoMFA method. The prediction power of the 
model was validated by estimating the IC50 values for an external test set including six 
compounds tested during the study. As a result, the predicted IC50-values of the test set 
differed from the actual values at most 0.67 log units giving r
2 
value 0.87 and q
2
 value 0.69 
with SDEP of 0.76, with three components. Stability of the q
2
 value was verified using 
PLS. The predicted IC50 values for the test set were approximately 0.05 log units of the 
actual values. As a conclusion, the produced CoMFA model can be considered highly 
predictive and statistically valid. The CoMFA model also confirmed the importance of 
hydrophobic interactions in binding to CYP1A2, as suggested in earlier studies, and 
pointed H-bonds and electrostatic field in agreement with other earlier studies. Graphical 
representation as a stereofigure of color contour maps can be found in the original article, 
and for further information on CoMFA models related to cytochrome P450s, the reader is 
referred to literature (Rao et al 2000, Ekins et al 2001, Poso et al 2001, Haji-Momenian et 
al 2003, Leonetti et al 2004, Rahnasto et al 2005, Korhonen et al 2007). 
 
In addition to PLS, there are other statistical tools available to convert information into a 
functional 3D-QSAR pharmacophore model, ranging from simple linear methods to more 
complicated methods used for large data set difficult to interpret (Chohan et al 2006). 
These methods are discussed briefly in the next chapter. 
35 
 
2.2.3   Machine learning methods 
 
Pharmacophore models generated using either classical or 3D-QSAR approach are mostly 
conducted using simple, linear statistical regression methods such as PLS (see previous 
chapter 2.2.2), MLR (multiple linear regression), PCA (principal component analysis) or 
PCR (principal component regression) (Chohan et al 2006). Supervised methods use 
information of the dependent variable to derive a predictive model, and to train the model 
using measured values of the property to be modeled e.g. LD25, IC50 or Ki (Leach 2001). In 
other words, supervised methods generate a function or model based on training set, and 
predicts values for an external set using the created function or model. Furthermore, non-
linear, more flexible methods are available, e.g. neural networks, recursive partitioning 
(RP) methods such as CART (classification and regression trees), k-nearest neighbor, DA 
(discriminant analysis) and SVM (support vector machine), naïve Bayesian classifier and 
logistic regression (Arimoto 2006, Chohan et al 2006). Methods using non-linear 
algorithms are applicable and superior to conventional linear regression, when the 
information available is relatively noisy, large at size and difficult to interpret as such. 
 
This is often the case with models related to CYPs obtained from a number of HTS assays, 
and it creates a demand for machine learning methods, which are capable of handling the 
data obtained (Arimoto 2006). Machine learning methods are techniques containing many 
algorithms to discover patterns and rules, and based on them, can be used as in silico filters 
being fast to run, accurate and global at nature, and also producing predictive and 
statistically significant information on cytochrome P450 ligand activity and their ADMET 
properties useful in early-phase virtual screening and compound library design (Byvatov et 
al 2003). 
 
When predictive QSAR models are generated, the most often used applications of machine 
learning methods are PLS-based classifiers (e.g. PLSDA) and different artificial neural 
networks (ANN) as well as SVM. SVM was originally introduced by Vaprik, as an 
alternative to ANN. From these methods, SVM and ANN produce more accurate 
predictions than PLSDA and overall, SVM has a higher capacity than ANN (Sorich et al 
2003). The main advantage of SVM is its relatively low sensitivity to data overfitting, 
which is based on structural risk minimization. Risk minimization principle means 
minimizing both training set error and generalization error simultaneously (Yap et al 
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2006). For example, SVM has been used with auspicious results in determining the 
concentration causing 50% inhibition of the turnover of a specific CYP3A4 substrate (IC50) 
with 1363 drug-like research compounds (Kriegl et al 2005). SVM was able to differentiate 
strong, medium and weak inhibitors in the test set with an accuracy of more than 70%. Yap 
and Chen (2005) used SVM with CYP3A4 and also with CYP2D6 and CYP2C9 in 
predicting substrates and non-substrates, as well as inhibitors and non-inhibitors of 
cytochrome P450 family, using 461 non-inhibitors and 334 non-substrates for CYP3A4, 
522 non-inhibitors and 504 non-substrates for CYP2D6, and 535 non-inhibitors and 558 
non-substrates for CYP2C9. As can be seen from the size of the compound database, 
machine learning methods can be used for extremely large data-sets compared to PLS, 
which usually consist of database of approximately 30 compounds (Leach 2001). The 
research of Yap and Chen (2005) proved also the predictive power of SVM, which can be 
even higher, when combined with other algorithms e.g., genetic algorithm (GA) in 
selecting the best descriptors for the models. 
 
Interestingly, in most researches, which have been focusing on cytochrome P450 
predictions based on machine learning methods, supervised techniques such as SVM have 
been utilized (Korolev et al 2003). However, also unsupervised methods, which do not 
have a priori output, are available. Unsupervised methods require less computer capacity, 
and their output is more flexible. Kohonen self-organizing map (SOM) or Kohonen neural 
networks (KNN) (Kohonen 2000) is an unsupervised machine learning method, which 
produces distance preserving 2D topological maps based on high-dimensional input 
information (Hasegawa et al 2002, Balakin et al 2006). The map can represent e.g. 
substrates of cytochrome P450s (vectorial samples) distributed based on information of 
their 3D-QSAR. Substrates with similarity in their molecular descriptors are located close 
to each other, with respect to their biological activity. Following from the nature of the 
output, the map can be used in visualization and/or classification of multivariate data. 
Korolev et al (2003) utilized SOM in determining the probability of a novel substrate to be 
metabolized via cytochromes. The database consisted of 2200 compounds representing 
substrates, non-substrates and metabolites of cytochrome P450 mediated reactions for 
extensive 38 human cytochromes. The input in their research can truly be considered as 
multivariate data. Nevertheless, SOM was still able to classify correctly 76.7 % of the 
substrates and 62.7 % of the metabolic products, with 12.6 % and 22.4 % of these falling 
into areas with no specific classification of being either substrates or metabolites, 
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respectively. However, the algorithm generated by Korolev et al could be successfully used 
in determining the susceptibility of a novel substrate to be metabolized by the cytochrome 
P450s in the early stages of drug discovery process. Also, it could be possible to predict the 
exact isoform of the substrate by using the SOM.  
 
SOM has also been utilized in classifying compounds based on their binding affinity 
towards cytochrome P450s (Balakin et al 2004). A dataset of 491 compounds with 
apparent Km values for human cytochrome P450s were analyzed with success. The SOM 
was able to correctly classify 97 % of CYP3A4 substrates with low Km (<10 µM) and 91 
% of compounds with high Km (>100 µM). Classification was conducted also for CYP2C9, 
2B6 and 2D6 but the research concluded more data being required, before statistically 
valid discrimination could be made between compounds with high and low Km. 
 
A short summation of machine learning methods used in cytochrome P450 predictions can 
be found in Table 4. Represented in the table are the overall accuracies for classification of 
inhibitors/non-inhibitors and substrates/non-substrates. In addition, machine learning 
methods have been used in predicting affinity and relevant binding conformations 
concerning cytochrome P450s (Bazeley et al 2006). Nevertheless, machine learning 
methods, too have limitations when the data set is considered unbalanced, e.g. if two 
classes, namely inhibitors and non-inhibitors of cytochrome P450s, differ much when 
considering the size of the groups (Eitrich et al 2007). To overcome the problem of biased 
results with large, unbalanced data, conventional machine learning methods can be further 
combined with additional algorithms for classification. These consensus models have been 
proven sensitive and accurate in recognizing cytochrome P450 inhibition potency of 
compounds (Chohan et al 2005, O'Brien and de Groot 2005, Yap and Chen 2005, Yap et al 
2006). 
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Table 4: Machine learning methods used in predicting cytochrome P450 inhibition 
potency 
 
Isoform/Property 
 
Method 
 
Overall accuracy 
 
Reference  
CYP3A4  
(inhibition) 
 
ANN 90 % Molnár and Keserü 
2002 
38 human CYPs 
(substrate/metabolite) 
KNN 76.7 % / 62.7 % Korolev et al 2003 
CYP3A4 
(high Km/low Km) 
KNN 91 % / 97 % Balakin et al 2004 
 
CYP1A2 
(inhibition) 
 
 
Consensus (PLS, MLR, 
CART, BNN) 
 
83 % 
 
Chohan et al 2005 
CYP3A4 
(inhibition /  
substrate) 
 
Consensus SVM  96 % / 95 % Yap and Chen 2005 
CYP2D6 
(inhibition /  
substrate) 
 
Consensus SVM 94 % / 95 % Yap and Chen 2005 
CYP2C9 
(inhibition /  
substrate) 
 
Consensus SVM 95 % / 97 % Yap and Chen 2005 
CYP2D6 
(affinity / binding 
conformations) 
 
ANN 85 ± 6 % Bazeley et al 2006 
CYP3A4  
(inhibition) 
SVM / LR / LDA / PLS /  
C4.5 DT,  kNN, PNN 
94.6 /87.8 /48.6/90.5/ 
87.8/98.6/87.8 % 
Yap et al 2006 
 
2.3   Quantum mechanical models 
 
Quantum mechanics (QM) describe the behaviour of matter and energy on the scale of 
atoms and sub-atomic particles; neutrons, protons and electrons. In quantum chemistry, the 
focus is in the electronic behaviour of atoms and molecules since electrons are greatly 
responsible for the chemical properties of atoms and molecules. In other words, it is 
possible to derive properties of molecular systems based on their electronic distribution 
(Groundwater and Taylor 1997, Leach 2001). However, solving the electronic behaviour is 
not a trivial task when considering complex systems as cytochrome P450s. The foundation 
for determining electronic behaviour of the target system is Schrödinger equation (Eq 2). 
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Schrödinger equation predicts the quantum mechanical energy levels, when given a 
collection of the spatial positions of atoms (wavefunctions) and the total number of 
electrons in the system (Dill and Bromberg 2003, Friesner 2005). In addition to obtaining 
information concerning energy of the system, Schrödinger equation provides facts about 
other related properties such as electron density. Although the equation in a compact form, 
as represented in Equation 2 might seem simple and straightforward, a detailed description 
of quantum chemical principles underlying Schrödinger equation is beyond this text and 
the reader is referred to literature (Leach 2001, Dill and Bromberg 2003).  
 
Hψ = Ejψ       Eq.2 
H: Hamiltonian operator, Ej: constant with eigenvalue and quantum number, ψ: 
wavefunction 
 
Simulating chemical reactions in which bonds are breaking and forming, requires using of 
QM methods since classical force fields are not capable of simulating such processes 
(Leach 2001). With CYP enzymes several studies have been conducted, using different 
QM methods concerning activation barriers for substrates and heme-oxygen species during 
the catalytic cycle, to predict regionally susceptible metabolic sites for the substrates (de 
Graaf et al 2005a). A more detailed description of the QM methods used in CYP 
applications is presented in chapter 2.3.1. 
 
QM models are based on quantum theories, which can be approached with different level 
of methods. Quantum theories include for example molecular orbital theory, Hückel 
theory, valence bond theory and density functional theory (DFT) (Leach 2001). From the 
theories, molecular orbital theory is the one most widely used. The methods underlying 
quantum mechanics include e.g., ab initio and semiempirical methods and their 
subcategories. Also, ab initio calculations can be conducted using either wavefunction-
based approach or DFT (Friesner 2005). Semiempirical calculations can be conducted 
using different methods such as PM3 (Parameterized Model 3) and AM1 (Austin Model 1), 
which apply the same theoretical assumptions, but differ in the approximations being made 
(Höltje et al 2003). The difference between ab initio and semi-empirical models is their 
way of reproducing experimental data, which ab initio does without using empirical 
parameters, contrary to semi-empirical methods. As such, ab initio is useful in situations, 
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where little - if any - information of the system of interest is available, since ab initio 
calculations are extremely expensive computationally (Höltje et al 2003, Friesner 2005). 
Semiempirical calculations can be considered filling a gap between ab initio methods and 
molecular mechanics (MM), which does not explicitly include electrons and nuclei of 
atoms in the calculations, and can be considered as a more simple method. Nevertheless, 
both ab initio and semiempirical methods are widely used in cytochrome P450 predictions 
as well as mixed QM/MM. 
 
When using QM/MM technology, a small part of the target system is treated with QM 
methods and the rest of system with MM methods. In most occasions, the core region 
treated with QM is embedded in the MM region of mixed QM/MM system (Figure 4). For 
example, in the case of cytochrome P450s, the heme moiety and its functions can be 
considered the core of the cytochrome chemistry, and are treated with accurate ab initio 
calculations. All the rest of the protein is treated with MM. QM/MM technology has been 
used e.g. by Guallar and coworkers (2002) in their research concerning the conversion of 
C-H bond into alcohol (hydroxylation) by cytochrome P450s. Using the mixed technology, 
they were able to compute relative energies of intermediates and transition states in 
cytochrome P450cam reaction cycle. The advantage of using such a mixed technology is 
being able to realistically model complex molecular systems with reasonable computer 
capacity compared to the whole enzyme being handled with exhaustive QM calculations. 
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2.3.1   Quantum chemistry in cytochrome P450 predictions 
 
Exceptionally large amount of experimental and theoretical work has been invested in 
understanding the complex reaction cycle of cytochrome P450s (Figure 2), and the effects 
of the cycle on specific ligands, and their metabolism at an atomic-level (Guallar et al 
2003).  The cytochrome P450 core chemistry can be considered as a large and complex 
field and following from this, accurate atomic-level calculations represent a severe 
challenge. Also, there are different opinions concerning the activation of O2 and the 
number of electrophilic oxidants participating in the catalytic reaction cycle (Shaik et al 
2004). As such, a complete description of the various steps in the cycle at atomic-level has 
yet to be produced. However, a detailed understanding of the mechanisms and underlying 
energetics of cytochrome P450 reactions would provide the means to build a quantitative 
model for predicting metabolism of pharmaceuticals and xenobiotics during the early 
stages of drug development (Bathelt et al 2004). The models could also be used in 
describing the absolute rate constants together with relative reactivity and energetics of 
enzymatic reactions, thus qualitatively enhancing understanding the chemistry underlying 
cytochrome P450s (Higgins et al 2001, Guallar et al 2002). As such, quantum chemistry 
calculations have been used in several occasions in order to help understanding the 
cytochrome P450 reaction cycle in detail.  Hydroxylation of alkanes and epoxidation of 
 
Figure 4: A schematic arrangement of QM/MM technique (Adapted 
from Höltje et al 2003). The small core region of QM is embedded in 
the MM region of the mixed system representing the areas of the target 
system where QM and MM methods are mostly applied. 
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alkenes have been the targets of the most extensive research efforts (de Visser et al 2001, 
Guallar et al 2002, Bathelt et al 2004). The energetics of the metabolism mediated by 
CYPs have been studied via hydrogen abstraction energy; the energy, which is required to 
withdraw a hydrogen atom from a cytochrome P450 substrate.  
 
For example, Higgins et al determined the hydrogen abstraction energy with respect to 
electronic and steric features affecting regioselectivity using several cytochrome P450 
isoforms (1A2, 2B1, 2B6, 2C8, 2C9, 2E1, 4B1). Semiempirical methods with AM1 and 
DFT calculations provided a quantitative description of relative energetics of oxidation at 
different positions in a set of substrates. Based on the relative energetics, it is possible to 
predict a catalytic site and metabolic pathway for substrates of different CYP isoforms. 
 
Singh et al (2003) developed a semiquantitative model for evaluating also the hydrogen 
abstraction energy for different sites in a drug molecule. In their study, 50 CYP3A4 
substrates were used in order to help decide the possible catalytic sites for CYP3A4-
mediated metabolism. The practical calculations were conducted using AM1 semiempirical 
molecular orbital calculations with trend vector analysis. Trend vector analysis is similar to 
QSAR PLS analysis. The results were compared to experimentally known major metabolic 
sites of CYP3A4 substrates, giving successful statistical values. The generated model can 
be used together with binding affinity information to predict possible substrates for CYP 
enzymes suggesting also their likely metabolic sites.  
 
Olsen et al (2006) conducted a similar kind of research, which determined the activation 
energy for hydrogen abstraction energies for 24 structurally diverse substrates with 
features such as primary, secondary and tertiary aliphatic carbon atoms, nitrogen, oxygen, 
sulphur and sp
2
 hybridized or aromatic carbon atoms next to a putative reactive atom, for 
which the hydrogen abstraction activation energy were calculated using DFT calculations 
and semiempirical methods. As a result, the highest activation barriers were obtained for 
sp
3
 hybridized carbon atoms, and lowest activation barriers were obtained for amine 
derivatives indicating the relative ease of the amines to be metabolized via cytochromes. 
The correlation between activation energy and molecular descriptors provided a model, 
which could be used as a filter for potential CYP substrates in early stages of drug 
discovery, providing also information of the putative catalytic site of the substrates. 
However, DFT calculations proved to be computationally extremely demanding, and took 
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CPU (central processing unit) time of several weeks for each substrate. As such, DFT 
calculations can not be considered to be used routinely as tools in cytochrome P450 
predictions. DFT-based filters for virtual screening of large databases would be 
computationally exhaustive, and CPU time required for screening all the molecules in the 
database is beyond imagination. With simpler semiempirical methods (e.g. AM1) excellent 
statistical values were still gained with the mean absolute errors being only 3-4 kJ/mol, 
when compared to full DFT calculations. Following from this, simpler quantum 
mechanical methods, such as semiempirical calculations would be more suitable for e.g. 
virtual screening of new, potent CYP substrates. The results of Olsen and coworkers are 
consistent with full DFT calculations being mostly reserved for special problems, such as 
complete description of the iron-porphyrin system of heme.  
 
A study conducted by Oda et al (2005) took a different approach focusing on force field 
parameters of the heme iron. The oxidation and spin state of the iron affect CYP substrate 
binding, so it is important to evaluate the spin states when performing molecular docking 
of substrates. Extensive quantum chemical chemical calculations were performed to obtain 
parameters describing interactions between cytochrome P450s and small ligands to be 
further explored in MM methods and classical molecular dynamics (MD) simulations. The 
research was conducted using both ab initio and semiempirical unrestricted Hartree-Fock-
methods. Contrary to the results obtained by Olsen et al (2006), their study concluded that 
DFT calculations gave seemingly more accurate results than semiempirical AM1 method 
which was not suitable for the iron of heme moiety, probably since AM1 does not include 
parameters for transition metals.  
 
As a conclusion, quantum chemical calculations can predict the relative reactivity for a 
substrate and cytochrome P450 enzyme but they cannot predict binding affinity or 
orientation of the potential substrates, which as a combination, can be considered the 
ultimate goal in computational modeling (Higgins et al 2001). As such, QM models have 
been widely used together with methods such as molecular docking and molecular 
dynamics simulations, which are further discussed in the following chapters. The 
cytochrome P450 predictions with QM models described here cover only a fraction of the 
overall researches conducted with this area, and the number of similar researches is rapidly 
growing with advances in theory, software and computational hardware, allowing creating 
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more accurate and efficient models concerning the processes governed by the cytochrome 
P450 superfamily (Friesner 2005). 
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3   PROTEIN-BASED MODELS 
 
Protein-based models derive information from the 3D structures of cytochrome P450 
enzymes. Main sources for protein-based models are X-ray crystallographic structures and 
homology models, which have been generated using the crystal structures as templates. 
Both methods provide detailed information of the binding cavity of cytochromes, and 
interactions between the active site residues and CYP substrates and inhibitors. To some 
extent, protein-based models can be considered complementary to ligand-based models.  
 
3.1   Crystallographic structures 
 
3D structures of proteins can be generated by either X-ray crystallography or nuclear 
magnetic resonance (NMR) spectroscopy in solution. Since crystal structures of proteins as 
such are slightly too rigid, and NMR models are too flexible, MD simulations are 
performed with crystal structures, to represent the situation resembling most the actual 
situation. Notably, cytochromes P450s are membrane-bound proteins and to prevent the 
aggregation of the protein while being crystallized, the membrane anchor sequence of the 
protein has to be removed (Cosme and Johnson 2000, Williams et al 2000). 
 
When a crystallographic structure of the target protein is available, the structures can be 
successfully used in identifying common features for a group of proteins. With 
cytochromes, the crystal structures have provided the means to compare the overall folding 
of CYPs, and to identify structurally conserved regions. Crystallographic structures have 
also provided the means to explore the access and exit channels, active site (volume) and 
flexible regions of the enzymes (Otyepka et al 2007). Following from this, the 
crystallographic structures provide opportunities to perform molecular dynamics 
simulations, which can be used in exploring the dynamic behavior of access and exit paths 
in the protein, as well as hydration of the active site during ligand-binding (de Graaf et al 
2005a). In addition, the crystal structures provide data complementary to experimental 
findings, and they can be used together with information gained from ligand-based models, 
allowing detailed understanding of the ligand-protein interactions.  
 
46 
 
At present, only a few crystallographic structures of mammalian cytochromes are available 
including CYP2A6, 2B4, 2C5, 2C8, 2C9, 2D6 and 3A4 (Otyepka et al 2007). The 
available mammalian cytochromes and their PDB ID-codes are represented in Table 5. 
When crystallographic structures are not available, alternative techniques are applied to 
achieve information concerning the 3D structure of the cytochrome P450s. Comparative 
modeling is a method, which is used in generating cytochrome homology models in the 
absence of crystallized structures. Comparative modeling technique is discussed in more 
detail in chapter 3.2. In the following, crystal structures available for mammalian 
cytochromes are discussed. Crystal structures are available also for bacterial CYPs, but the 
focus of this research lies in mammalian CYPs. Nevertheless, the role of bacterial CYPs 
cannot be underestimated, since crystal structures of these cytochromes have provided the 
basis for understanding the structure and properties of mammalian cytochromes, and the 
bacterial cytochromes P450cam (CYP101) and P450BM-3 (CYP102) have been used in 
several occasions as templates for homology protein models of CYP2A, 2B, 2C, 2D 2E, 
3A and 4A (Lewis 2002a, b). A detailed overview concerning the bacterial CYPs can be 
found in literature (Wade et al 2004, Cojocaru et al 2007).  
Table 5: Published mammalian cytochrome P450 crystal structures 
CYP Species PDB ID Ligand Reference 
2A6 Human 1Z10 Coumarin Yano et al 2005 
2A6 Human 1Z11 Methoxsalen Yano et al 2005 
2B4 Rabbit 1PO5 - Scott et al 2004 
2B4 Rabbit 1SUO 4-(4-chlorophenyl)-imidazole Scott et al 1004, 
Hernandez et al 2006 
2B4 Rabbit 2BDM Bifonazole Zhao et al 2006, 
Hernandez et al 2006 
2C5 Rabbit 1DT6 - Williams et al 2000 
2C5 Rabbit 1N6B Dimethylsulfaphenazole Wester et al 2003a 
2C5 Rabbit 1N6R Diclofenac Wester et al 2003b 
2C8 Human 1PQ2 Palmitic acid Schoch et al 2004 
2C9 Human 1OG2 - Williams et al 2003 
2C9 Human 1OG5 S-warfarin Williams et al 2003 
2C9 Human 1R9O Flurbiprofen Wester et al 2003c 
2D6 Human 2F9Q - Rowland et al 2006 
3A4 Human 1TQN - Yano et al 2004 
3A4 Human 1W0E - Williams et al 2004 
3A4 Human 1W0F Progesterone Williams et al 2004 
3A4 Human 1W0G Metyrapone Williams et al 2004 
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3.1.1   CYP2A6 
 
CYP2A6 is an isoform, which metabolizes approximately 4 % of drugs metabolized by 
cytochrome P450s (Lin and Lu 2002). Despite its relatively small contribution to 
metabolism, CYP2A6 participates in the detoxification of nicotine, and in activation of 
tobacco-specific procarcinogens to mutagenic products (Kim et al 2005, Yano et al 2005). 
At the moment, two X-ray structures of the isoform are available with bound coumarin and 
methoxsalen. Exploring the CYP2A6 structure has revealed the isoform sharing a common 
fold with other cytochromes, but the active site is seemingly smaller; 25 % smaller volume 
than e.g. CYP2C8, 2C9 and 3A4. The active site is hydrophobic and contains one 
hydrogen-bond donor. This is consistent with the structures of known CYP2A6 substrates, 
which are usually small and planar, hydrophobic molecules. However, the characteristics 
of the active site indicate the conformation of peptide backbone being different when 
compared to other cytochromes, thus complicating the comparison of ligand-protein 
interactions with other cytochromes. The X-ray structure of 2A6 is being further studied 
using random mutagenesis and fluorometric high-throughput screening, in order to study 
the structure-activity relationships with CYP2A6, which will hopefully reveal more of the 
structure of the isoform (Kim et al 2005). 
 
3.1.2   CYP2B4 
 
For CYP2B4, three different crystal structures are available, which include a high-
resolution ligand-free structure with resolution of 1.6 Å, and two structures with bound 
substrates, namely bifonazole (BIF) and 4-(4-chlorophenyl)-imidazole (4-CPI) (Hernandez 
et al 2006). The crystal structures of the isoform have revealed large conformational 
changes in flexible regions, which are able to change the active site properties dramatically 
(Zhao and Halpert 2007). The BIF-bound crystallographic structure also pinpointed a 
remarkable ligand-induced flexibility in the structure compared to the ligand-free crystal 
structure, which is already in an open conformation contrary to the complex with 4-CPI, 
which is considered to be in a closed conformation. Based on this information, a site-
directed mutagenesis study was conducted based on the crystal structure to determine 
important amino acids for ligand binding (Hernandez et al 2006). Six residues interacting 
with either or both of the bound ligands were replaced with smaller and/or bulkier residues, 
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showing that only a mutant I363A perturbed significantly the enzyme inhibition and 
catalysis. Further studying of the conformational flexibility was conducted using imidazole 
inhibitors, but the research concluded more experimental data being needed before final 
conclusions could be made concerning the residues important to substrate binding 
(Muralidhara et al 2006).  
 
3.1.3   CYP2C5 
 
CYP2C5, which catalyzes the hydroxylation of progesterone, was the first crystal structure 
of the mammalian cytochromes (Johnson et al 2002). The crystal structure showed the 
active site clearly diverging from the most closely related microbial enzyme P450 BM3 
(CYP101; Bacillus megaterium), and pinpointed the possibility of induced fit or movement 
of the protein around substrate-binding pocket (Williams et al 2000). The functionally 
important residues affecting substrate specificity and regioselectivity (SRSs) were found to 
be conserved in the proximal face of the isoform. At the moment the crystal structure of 
CYP2C5 is available bound with anti-inflammatory drug diclofenac at a resolution of 2.1 
Å (Wester et al 2003a), and complexed with sulfonamide DMZ at a resolution of 2.3 Å 
(Wester et al 2003b).  Also a free structure of CYP2C5 is available (Williams et al 2000). 
CYP2C5 crystal structure has been used as a template structure for several cytochrome 
homology models (Lewis 2002, Kumar et al 2003, Stahl and Höltje 2005).  
 
3.1.4   CYP2C8 
 
The crystal structure of human CYP2C8 was determined at a resolution of 2.7 Å (Schoch 
et al 2004). CYP2C8 is the primary enzyme metabolizing cerivastatine, and the isoform 
participates in the metabolism of natural substrates e.g. unsaturated fatty acids and retinoic 
acids (Marill et al 2000). By exploring the crystal structure, the active site of the isoform 
was determined to be larger than the active site of CYP2C5, due to bulky residues 
surrounding the active site (Schoch et al 2004). The observation is consistent with the 
ability of CYP2C8 to metabolize relatively large molecules, which are poor substrates for 
other CYP2C family enzymes. Also other structural differences occur when the crystal 
structure was compared to previously crystallized isoforms of the same subfamily, mostly 
concentrated in the F/G-loop region and other regions at close proximity to the active site. 
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3.1.5   CYP2C9 
 
For the cytochrome 2C9, three x-ray crystallographic structures are available (Otyepka et 
al 2007). CYP2C9 is an isoform, which can cause severe adverse effects with drugs having 
low therapeutic margin e.g. warfarin and phenytoin, due to its polymorphism (Wester et al 
2004). The crystal structure of CYP2C9 has been generated complexed with flurbiprofen 
and S-warfarin (Williams et al 2003, Wester et al 2003c) and also, in a ligand-free 
conformation. The crystal structures revealed the catalytic site of the isoform to differ 
significantly in conformation when compared to other CYP2C family enzymes (2C5, 2C8), 
and the ligand-free crystal structure differed from the crystal structures complexed with the 
substrates. Most of the differences were observed in the N-terminal parts, B/C-loops, F 
helices and F/G-loops of the cytochromes, and may be reflecting the conformational 
flexibility of CYP2C9. 
 
3.1.6   CYP2D6 
 
CYP2D6 is a widely studied isoform of the cytochrome P450 superfamily, metabolizing 
approximately 20 % of the known drugs, particularly a variety of central nervous system 
and cardiovascular drugs (Rowland et al 2006). Many genetic polymorphisms have been 
described for CYP2D6, which is one reason for the myriad number of researches 
concerning the isoform. The crystal structure of CYP2D6 has been solved with a resolution 
of 3.0 Å, possessing a fold characteristic to other cytochromes. The active site cavity is 
well defined, containing residues considered important for substrate recognition and 
binding, namely Asp-301, Glu-216, Phe-483 and Phe-120. Although the F-G-loop of 
CYP2D6 could not be modeled entirely, the crystal structure was able to explain much of 
the reported site-directed mutagenesis data (Mackman et al 1996, Kirton et al 2002, de 
Graaf et al 2006). 
 
3.1.7   CYP3A4 
 
For CYP3A4, which is the cytochrome responsible for the metabolism of most of the 
known pharmaceutical agents, several crystal structures are available. In addition to the 
first crystal structure of the isoform with 2.05 Å resolution (Yano et al 2004), another 
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ligand-free and two structures complexed with an inhibitor metyrapone and a substrate 
progesterone, have been generated (Williams et al 2004). The most distinct difference 
between the crystal structures is the size of the active site. Yano et al (2004) describe the 
substrate binding cavity relatively large contrary to Williams et al (2004), who claims the 
active site being small with little conformational changes associated with binding of a 
substrate or inhibitor. Of course, the size of the active site can be considered in a somewhat 
subjective way, but the former description of the active site is consistent with models, were 
two or more molecules occupy the active site at the same time. In a more recent study, with 
regard to the structural basis for CYP3A4 in complex with large ligands, crystal structures 
of CYP3A4 with bound ketoconazol and erythromycin have been generated (Ekroos and 
Sjögren 2006). The results from the study show the protein undergoing dramatic 
conformational changes with ligand-binding and allowing several binding modes for 
substrates. The results reveal the extreme flexibility of CYP3A4 upon ligand binding, and 
represent severe challenges for computational modeling of the isoform. These results are 
congruent with the known ability of CYP3A4 to bind structurally diverse substrates. 
 
3.1.8   Cytochrome P450 crystal structures: summation 
 
Based on the crystal structures of cytochromes, it has been possible to make conclusions 
regarding the overall structural characteristics of the cytochromes. The cytochromes 
consist mainly of four β-sheets and approximately 13 α-helices with an insertion called J' 
(Graham and Peterson 1997). The active site, which locates deep inside the cytochromes, is 
generated by a four-helix bundle composed of helices D, E, I and L together with helices J 
and K. Between the helices I and L lies the heme template, which is linked to the protein 
structure via sulphur atom of cysteine residue near the heme. The cysteine is a fifth ligand 
of the heme iron. The sixth coordination position is occupied by either water, oxygen, or 
the substrate depending on the location in the reaction. Characteristic to the cytochromes 
seems to be the F/G segment, which is perpendicular to structurally conserved helix I 
(Otyepka et al 2007). F and G helices together with the F/G-loop and B/C-loop control the 
cytochrome active site. The general structure with heme-binding structural core of the 
cytochromes can be considered relatively conserved. Still, variable regions are found when 
comparing the crystal structures, the differences focusing around the deeply buried active 
site and F/G-loop, respectively. The variable regions are mostly associated with substrate 
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recognition, substrate binding and redox partner binding, which presents a challenge for 
deriving overall quality model concerning the cytochromes but explain the substrate 
specificity of the cytochromes. 
In addition for gaining information of the similar and variable regions cytochromes and 
their subfamilies, the crystal structures have been found useful in studying cytochrome 
access channels, which are considered as pathways connecting the active site with protein 
surface (Cojocaru et al 2007). The active site is located deep inside the cytochromes, 
isolated from the bulk solvent and the cytochrome substrates, which are predominantly 
hydrophobic molecules, have to make their way inside the buried active site (Graham and 
Petersen 1999, Wade et al 2004). By exploring the crystal structures of both bacterial and 
mammalian CYPs, the proteins are considered to go through dynamic motions resulting in 
opening and closing these channels when the substrates are entering the active site, or 
metabolized products are leaving the reaction site. The dynamic motions are considered to 
have an effect on CYP substrate specificity as well as enzyme kinetics, and they are also 
likely to participate in transporting molecular oxygen and water molecules in the active 
site, which is crucial for cytochrome activity to occur (Cojocaru et al 2007). However, the 
research concerning the complex nature of the substrate access channels has not yet 
resulted in overall description of the nature of these pathways. 
 
3.2   Homology models 
 
Comparative modeling is a technique, which produces models of protein structures, 
namely homology models, based on information gained from a crystal structure of a known 
protein. Secondary and tertiary structure of an unknown cytochrome can be predicted 
based on an amino acid sequence of a crystallized protein, since proteins with high degree 
of similarity adopt similar 3D conformation.  
 
Homology models provide valuable information of cytochromes and their subfamilies 
when experimentally determined structures of target proteins are missing (Kirton et al 
2002). This is often the case when considering cytochromes, since only a few 
crystallographic structures of the cytochromes are available as discussed in previous 
chapters. 
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3.2.1   Comparative modeling technique 
 
Comparative modeling as such is an iterative process, which has been represented in 
Figure 5. The method starts with a determined amino acid sequence of a target protein 
belonging to a particular protein family (Höltje et al 2003). The next stage in the process is 
identification of template structures, by scanning the amino acid sequence of target protein 
against sequences with a known crystal structure e.g. in the Brookhaven Protein Data Bank 
(Kirton et al 2002, Lewis et al 2002, Höltje et al 2003). Based on the sequence similarity, 
3D structure of the target protein can be deduced, since it has been observed that similar 
amino acid sequences tend to adopt similar 3D conformation (Chothia and Lesk 1986). 
Consequently, high similarity between target and template sequences produces better 
alignments and consequently, more accurate homology models (Martin et al 1997). 
However, it has also been suggested that multiple templates even with relatively low 
sequence similarity, can produce homology models of good quality since a better 
description of the overall structure of the target protein is available using multiple 
templates (Kirton et al 2002).   
 
After finding suitable template structures, multiple sequences are aligned with respect to 
each other, including the sequence of the target protein to locate structurally conserved 
regions (SCRs) (Kirton et al 2002). SCRs are known to be relatively similar across the 
cytochrome P450 superfamily, and can be considered straightforward to locate and model 
by aligning either the amino acid sequencies or the 3D crystal structure of template with 
the sequence of the target protein, and then placing the regions in 3D space (Höltje et al 
2003, Mestres 2005). With cytochromes, SCRs mostly comprise a set of α-helices (E, J, K, 
K´, K´´, L, part of J) and β-sheets (6-1, 1-3, 3-2), as well as the active site of the protein 
together with the Cys-pocket (Kirton et al 2002, Mestres 2005). The alignment of 
templates and target is validated and refined at every step of process, using e.g., mutational 
studies and isoform specificity data to verify the location of SCRs, with respect to 
experimental data concerning the substrate recognition sites (SRSs) (Gotoh 1992, de Graaf 
et al 2005).  
 
Additionally, structurally variable regions (SVRs) and side chain conformations are 
identified based on alignment of the templates and the target. SVRs usually locate in the 
membrane bound termini, B'-helices and F/G-loop regions of cytochromes, and modeling 
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of SVRs with reasonable accuracy is considered a demanding task (Kirton et al 2002, 
Höltje et al 2003, Mestres 2005). SVRs may contain deletions and insertions in their amino 
acid sequence and may in general possess little - if any - sequence similarity. However, 
they can modeled by examining homologous protein models, an building a corresponding 
segments based on information of the known structure, or using other methods such as 
loop search method and de novo generation technique (Höltje et al 2003).  
Side chain conformations can also be determined by examining the alignment of templates 
and target structure or structures of homologous proteins, and transferring the coordinates 
from highly similar template structures to the modeled target structure (de Graaf et al 
2005a). However, since side chains can adopt versatile conformations and degree of 
freedom, on some occasions modeling of side chains can be a complex task (Höltje et al 
2003). After adding missing side chain atoms, and generating conformations for the 
residues and possible loops, the structure of the homology model is optimized and 
validated using MD simulations, energy minimization and simulated annealing (Bathelt et 
al 2002, Höltje et al 2003, de Graaf et al 2005a). 
 
Finally, the generated homology model is again validated to verify the quality of the model 
(Kirton et al 2002, Höltje et al 2003). The generated homology model can be validated by 
comparing the root mean square deviation (RMSD) of the protein backbone and the 
conformations of the sidechains, with the template structure possessing highest sequence 
similarity or with an available, high-resolution crystal structure from the same enzyme 
family (Chothia and Lesk 1986, Martin 1997). However, the validation should mostly be 
conducted based on experimental data such as mutagenesis studies and predictions of the 
cytochrome P450 substrate/inhibitor binding and the site of metabolism with molecular 
docking and MD simulations (de Graaf et al 2005a).  
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3.2.2   Comparative modeling of cytochrome P450 structures 
 
Comparative modeling has been used in generating several homology models, which have 
produced further information concerning the cytochrome P450 structure and overall 
characteristics. Some of the available mammalian cytochrome P450 homology models are 
represented in Table 6. For example, based on the crystal structure of CYP2C5, homology 
models have been generated for several other cytochromes (CYP1A2, 2A6, 2B6, 2C9, 
2C8, 2C19, 2D6, 2E1 and 3A4) (Lewis 2002). The homology model of CYP2B6 is 
discussed in more detail in a separate chapter since it is the target of the experimental part 
of this work. The homology models provide detailed information concerning the putative 
active sites and important residues of cytochromes, and as such make it possible to design 
novel substrates and inhibitors for specific enzymes. Based on the homology models, it has 
also been possible to determine closely related cytochromes allowing identifying 
characteristic features of the mammalian cytochromes. 
 
Homology modeling has also been shown to contribute in understanding towards another 
member of the cytochrome P450 family, CYP11A1 (Storbeck et al 2007). CYP11A1 
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Figure 5: A flow chart representing the iterative process of comparative modeling. Adapted 
and compiled from Kirton et al 2002 
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participates in steroidogenesis by catalyzing the conversion of cholesterol to pregnenolone 
and following from this, the isoform is of physiological importance. However, CYP11A1 
has not been crystallized, and only a limited amount of structural information has been 
available. Using bacterial cytochromes, P450BM-3 and P450terp (CYP102 and CYP108) 
and the crystal structure of CYP2B4 as templates, a homology model of the protein has 
been generated (Muller et al 1998). The homology model of CYP11A1 has been 
successfully used in studying the mitochondrial electron transfer system of steroidogenesis 
in more detail, and it has also provided insight concerning the active site and the access 
and exit channels of the isoform, as well as its interactions with mitochondrial membrane. 
All this information was far beyond reach before a homology model of CYP11A1 was 
generated (Storbeck et al 2007). 
 
Notably, for the cytochromes many homology models have been generated based on the 
latest crystal structures. For example, after determining the crystal structure of CYP2C9, a 
new homology model was constructed for CYP2C19, in order to study the structure-
activity relationships between the isoform and its ligands (Wang et al 2007). As a result, 
the binding pockets of CYP2C9 were explicitly defined together with key features of 
potent inhibitors and residues important to catalytic activity. As such, the information can 
be exploited in designing personalized drugs as well as predicting the ADMET properties 
for novel substrates.  
 
The quality of the homology models is directly dependent of the quality of available crystal 
structures. Despite this, the homology models cannot be considered merely as secondary 
models since they produce detailed information of the active site characteristics, ligand-
protein interactions and the overall 3D structure of the target protein, in the absence of a 
crystal structure. Comparative modeling provides a powerful tool when combined with 
other computational approaches (ligand-based models, molecular docking, molecular 
dynamics simulations) to predict cytochrome P450 substrate selectivity and isoform 
specificity, as well as possible metabolic pathways and sites for metabolism, to further 
improve the development and discovery of new potent substrates. 
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Table 6: Homology models of cytochrome P450s generated using comparative modeling 
technique 
 
CYP 
 
Template 
 
Reference 
1A1 2C5 Szklarz and Paulsen 2002 
1A2 2C5 Kim and Guengerich 2004 
2A6 2C5 He et al 2004 
2A13 2C5 He et al 2004 
2B6 2C5 Bathelt et al 2002, Wang and 
Halpert 2002 
2C18 2C9 Payne et al 1999a, Oda et al 2004 
2C19 2C5, 2C9 Payne et al 1999a, Oda et al 2004, 
Wang et al 2007 
2E1 2C5 Lewis 2000, Lewis et al 2003, 
Danko et al 2006 
4A11 CYP102 Chang and Loew 1999 
11A1 2B4 Storbeck et al 2007 
17alpha BMP Auchus and Miller 1999 
19 (human aromatase) 2C9 Favia et al 2006 
27A1 several Prosser et al 2006 
 
3.3   The homology model of CYP2B6 
 
By now there is no x-ray structure of CYP2B6 available. However, a homology model of 
the enzyme has been built by Bathelt et al (2002), using CYP2C5 of rabbit as a template 
structure since the two isoforms share 48 % sequence similarity. Significantly, CYP2C5 
lacks residues forming F-G-loop and before a model of CYP2B6 could be constructed, the 
missing loop had to be modeled. However, at the time Bathelt and co-workers modeled 
CYP2B6, no other crystal structures of mammalian cytochromes were available. 
Consequently, crystal structures of bacterial cytochrome, CYP BM-3 in an open and closed 
conformation, were chosen as a model for the missing F-G-loop in CYP2C5 although the 
particular region in bacterial CYPs is shorter. Nevertheless, with small adjustments the 
missing loop was modeled, and MD simulations with simulated annealing were applied to 
the CYP2C5 structure. The quality of the produced CYP2C5 was tested with unconstrained 
MD simulations in water, in which the protein structure denatures in the simulation, if it is 
not folded into its native state. As such, unconstrainded MD simulations are considered an 
extremely sensitive test for quality (Chang and Loew 1997).  
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Based on sequence alignment with CYP2C5, the model of CYP2B6 was successfully 
constructed. Validation of the homology model was also conducted with unconstrained 
MD simulations in water to measure the stability of the CYP2B6 model. The RMSD 
between the backbone atoms of CYP2B6 model, and the minimized CYP2B6 model after 
heating and releasing the backbone, was determined to be less than 1.7 Å, which points out 
that only small differences can be found between the structures of CYP2C5 and CYP2B6.  
 
The homology model of CYP2B6 was further validated using manual docking of two 
substrates, cyclophosphamide (CPA) and ifosfamide (IFA) into the active site of the 
protein.  CPA and IFA can be metabolized via two alternative pathways by CYP2B6, and 
by docking the substrates, it was determined whether the substrate moiety to be 
metabolized could reach the heme iron in a preferred orientation for metabolism to occur 
and without clashes with CYP2B6. 
 
Based on the homology model, information of the putative active site of CYP2B6 and the 
residues important for substrate binding and activity has been suggested. The active site of 
the enzyme locates in the core of the enzyme, above the heme-thiolate group forming of 
three, mostly hydrophobic pockets. The most important pocket is the “heme pocket”, 
where the substrate moiety to be metabolized has to enter. In the model of Bathelt and co-
workers, all the pockets can be filled without clashes, when the substrate enters the active 
site in a preferred orientation for metabolism. The residues lining the pockets are 
considered major structural elements for regioselectivity of CYP2B6 (Table 7). Additional 
SRS (substrate recognition site) residues have been proposed based on several site-directed 
mutagenesis studies (Domanski et al 1999, Domanski and Halpert 2001, Spatzenegger 
2003). The SRS residues of CYP2B6 have been compared with CYP2B1 SRSs and 
CYP2E1 SRSs, and mutated in order to find out if the metabolism of CYP2B6 substrates 
RP73401 and 7-ethoxy-4-trifluoromethylcoumarin (7-EFC) would be affected. The studies 
indicated direct interaction with RP73401 and L363 and non-direct interaction with 
RP73401 and F107. L363 and T292 were suggested to participate in 7-EFC O-
deethylation, which is consistent with information gained from pharmacophore modeling 
of CYP2B6 substrates. 
 
58 
 
Table 7: Residues lining the binding pockets of CYP2B6 (Bathelt and co-workers 2002). 
 
Pocket 
 
Residues 
A: Heme pocket  Ala298, Thr302, Leu363, Phe206 
B: Side pocket Ser294, Ile114, Phe297, Phe115 
C: Roof pocket Ile209, Val447, Leu216, Val367 
 
3.3.1 Pharmacophore models of CYP2B6 
 
Pharmacophore models determining the structural elements important for CYP2B6 activity 
have been constructed by Wang and Halpert (2002) and Ekins et al (1999b). In both 
studies, pharmacophore models included one hydrogen bond acceptor and hydrophobic 
regions. In the pharmacophore model of Wang and Halpert two hydrophobic regions where 
included, while in the model of Ekins and co-workers three hydrophobic regions were 
located in different relative positions to each other. Wang and Halpert produced two 
pharmacophore models for CYP2B6 substrates, and by mapping benzyloxyresorufin and 7-
EFC into the pharmacophore models, they revealed the residues lining the modeled 
hydrophobic regions depending of the position of the substrate. Benzyloxyresorufin has 
two phenyl rings in its structure, fitting into hydrophobic regions H1 and H2 of the first 
pharmacophore model (A), and the oxygen atom of one of the ring acts as hydrogen bond 
acceptor. In their research, Wang and Halpert concluded that the oxygen is able to form a 
hydrogen bond directly with the active site of the enzyme or via a water molecule. 
However, when benzyloxyresorufin was docked into the active site of the homology model 
of CYP2B6, no hydrogen bond was identified between the molecule and CYP2B6. The 
findings suggests to the possibility of a water molecule participating in the hydrogen 
bonding with benzyloxyresorufin.  
 
7-EFC was successfully fitted with the other pharmacophore (B) model created by Wang 
and Halpert, in which one of the rings of 7-EFC and its trifluoromethyl substituent can be 
fitted into hydrophobic regions H3 and H4, whereas the oxygen atom on one of the rings of 
7-EFC acts as potential hydrogen bond acceptor. Residues at a distance of 5 Å from the 
hydrophobic regions H1, H2, H3 and H4 are represented in Table 8. Representations of the 
two pharmacophore models can be found in the original literature (Wang and Halpert 
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2001). The residues lining the hydrophobic regions are consistent with previous site-
directed mutagenesis studies, in which amino acid residues being important for the 
substrate metabolism in CYP2B subfamily were determined (Domanski et al 1999, 
Domanski and Halpert 2001). Following from this, the residues were located from the 
CYP2B6 homology model applied in the experimental part of this work, in order to 
determine the active site of the enzyme. The information of the active site was then 
exploited in the molecular docking of compounds into the homology model, and in 
interpreting the quality of the results based on their orientation in the active site and their 
position relative to the site of metabolism.  
 
Contrary to the pharmacophore models of Wang and Halpert, the pharmacophore model of 
Ekins and co-workers consisted of three hydrophobic regions, in addition to one hydrogen 
bond acceptor. The hydrophobic regions were located at distances of 5.3, 3.1 and 4.6 Å 
from the hydrogen bond acceptor with intermediate angle of 72.8˚ and 67.6˚. 
Representation of the pharmacophore model can be found in the original literature (Ekins 
et al 1999b). Two substrates, 7-EFC and S-mephenytoin were successfully fitted with the 
pharmacophore model and Km values were predicted with good estimations for both of the 
substrates when compared to the observed Km values.  
 
The substrates succesfully fitted into CYP2B6 pharmacophore models both by Wang and 
Halpert and Ekins and co-workers were applied in the experimental part of this work as a 
part of a set of known substrates of CYP2B6, which were selected reference structures 
when confirming the usability of CYP2B6 homology model.The results obtained from our 
studies were also compared to the pharmacophore models with respect to the mutagenesis 
studies performed for residues of CYP2B6 active site. 
Table 8: Residues lining the hydrophobic regions determined by pharmacophore 
modeling (Wang and Halpert 2002). 
 
Region 
 
Residues wild type 
 
Residues homology model 
H1 114, 115, 206, 298, 363, 367, 477 [84], [85], [176], [328], [333], [447] 
H2 206,297,298,301,302, 363, 477, 478 [176], [267], [268], [271], [272], 
[333], [447], [478] 
H3  206, 298, 302, 363, 367, 477, 478 [176], [268], [272], [333], [337], 
[447], [448] 
H4 301, 302, 305, 306, 362, 363, 477, 479 [271], [272], [275], [276], [332], 
[333], [447], [479] 
60 
 
4   LIGAND-PROTEIN INTERACTIONS 
 
So far this research has been focusing on ligand- and protein-based models separately. 
However, considering both of these approaches together, a wealth of detailed information 
concerning interactions between ligands and protein is achieved. 
 
One of the main motives in successful drug research and discovery is to identify relatively 
small molecules with high binding affinity and selectivity towards its receptor (Krovat et al 
2005). If such a molecule also possesses reasonable ADMET-profile, the possibility of 
late-stage attrition is reduced. 3D crystal structures of cytochrome P450s together with a 
bound substrate represent the means to study the behaviour of the molecules in the binding 
pockets as well as the way they interact with a receptor, using different computational 
approaches. One of these approaches is molecular docking protocol. “However, since only 
a few 3D crystal structures of cytochrome P450s togetherwith a bound ligand as well as 
plain 3D structures are not  
 
Molecular docking programs are used in predicting energetically favorable binding 
conformations and orientations of small molecules within the active site of target protein 
(Kitchen et al 2004, de Graaf et al 2005a). The binding affinity of the molecules can be 
further explored using approaches such as scoring functions and free energy perturbation 
calculations, which estimate the free energy of ligand-protein binding (Oprea and Marshall 
1998). However, docking approach lacks the ability to take into account full flexibility of 
ligand-protein complex which is an important point of view when considering cytochrome 
P450s (de Graaf et al 2005a). Nevertheless, most docking programs are capable of 
considering ligand-protein complexes as partially flexible systems. Molecular dynamics 
(MD) simulations are an alternative way to explore ligand-protein complex. MD 
simulations include internal flexibility and conformational changes of the system when 
considering ligand-protein interactions. In the following chapters, molecular docking, 
molecular dynamics simulations and binding affinity predictions are considered in more 
detail. 
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4.1   Molecular docking 
 
Molecular docking approach aims to predict energetically favourable conformation and 
orientation of a ligand when it binds into the active site of a protein (Kitchen et al 2004, 
Sousa et al 2006). Several algorithms are available concerning molecular docking, which 
differ in the level approximations they use in predicting ligand-protein interactions. 
Significantly, the docking protocol is a combination of search algorithms for energetically 
favorable conformations and scoring functions of the obtained results. For clarity, 
molecular docking and scoring functions are discussed in separate chapters although they 
are applied simultaneously when ligand-protein interactions are being explored. 
 
Approximations within algorithms generated for molecular docking are made, since 
biological systems such as cytochrome P450s are very dynamic in nature and possess 
substantially flexibile structures, making it necessary to reduce the dimensionality of the 
system in order to provide fast and effective computational tools. Following from this, the 
docking procedures consider ligand-protein interactions in three different way, namely  1) 
treating both ligand and protein as rigid molecules, 2) treating the ligand as flexible 
molecule (semi-flexible docking) or 3) treating both ligand and protein as flexible 
molecules (fully flexible docking) (Höltje et al 2003).  Notably, although considered as a 
fully flexible docking approach, the flexibility of the protein is limited to specific 
sidechains of the active site. The approaches and algorithms used in automated molecular 
docking are represented in Figure 6. Additionally, the molecular docking approaches can 
be divided into stochastic or deterministic algorithms depending of the reproducibility of 
the docking results or into incremental construction methods. However, in this research the 
docking approaches are divided according to flexibility, which is an important 
characteristic contributing to the interactions between cytochrome P450s and their 
substrates.  
 
A common approach is to use semi-flexible docking since rigid-body approximations 
ignore the importance of flexibility and on the other hand, fully flexible docking is 
computationally very demanding compared to other methods.  With cytochrome P450s, the 
most common docking algorithms applied include GOLD, FlexX, DOCK and AutoDock 
which belong to the category of semi-flexible approximations (de Graaf et al 2005a). 
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Although fully flexible docking approaches produce results with higher accuracy 
concerning the true nature of ligand-protein interactions, fully flexible docking is not yet 
used in regular basis when ligand-protein interactions are concerned due to the extensive 
computer capacity, which the approach requires (Sousa et al 2006). In addition to 
flexibility, accuracy of docking results is dependent also of the physicochemical properties 
of ligand-protein interactions, the quality of target protein structure and whether or not 
water molecules are included in the docking (de Graaf et al 2006, Krovat et al 2005). 
 
As mentioned, the flexibility of cytochrome P450s is an important factor contributing to 
the ligand-protein interactions. Thus, it should not be excluded when ligand-protein 
interactions are examined with molecular docking. Moreover, the cytochrome P450s 
represent a challenge for molecular docking since the proteins include heme moiety with 
metal ion and water molecules in their active site which are known to participate in the 
ligand-protein interactions in addition to the discussed structural flexibility and 
conformational changes during ligand binding (de Graaf et al 2005a). Since most docking 
procedures ignore water-mediated interactions, the accuracy of molecular docking can be 
limited when considering cytochrome P450s. However, if water is included in the dockings 
at the correct position, the accuracy of results improves, which has been demonstrated by 
de Graaf et al (2005b). By including different water scenarios into cytochrome P450 
dockings (water-free active sites, active sites containing crystallographic water molecules 
and water molecules predicted with GRID program), the accuracy of docking results in 
reproducing experimentally determined binding modes was improved. The accuracy of the 
results was validated by comparing catalytic site predictions to experimental data and 
RMSD between heavy atoms in reference protein structure and ligand docking poses. 
 
However, when docking cytochrome P450 substrates of variable sizes, merely including 
water is not enough; differently shaped and sized solvated protein binding pockets could 
further improve the accuracy of docking results (de Graaf et al 2005b). However, more 
computational power would be required, which is contradictory with docking approach 
having to be fast to influence decision making in chemical synthesis during early phases of 
drug development process (Shimada 2006).  
 
63 
 
Molecular docking has been successfully used in several cytochrome P450 predictions, for 
example in site-directed mutagenesis studies concerning CYP2B6, 2C8 and 2E1 
(Spatzenegger et al 2003, Melet et al 2004) and in refining and validating  CYP2B6 
pharmacophore models (Wang and Halpert 2002) as well as homology models of CYP1A2 
(Lozano et al 1997) CYP2B6, (Bathelt et al 2002), CYP2C8/9/18 (Riddeström et al 2001, 
Oda et al 2004), CYP2D6 (de Graaf et al 2006), CYP2E1 (Park and Harris 2003) and 
CYP3A4 (Szklarz and Halpert 1997). Successful predictions have also been made 
concerning the binding modes and catalytic sites for CYP2D6 and CYP3A4 ligands (de 
Graaf et al 2005b, Kirton et al 2005, de Graaf et al 2006, Zhou et al 2006).  As such, 
molecular docking can be considered a powerful and versatile tool in early stages of drug 
development process in producing qualitative information concerning ligand-protein 
interaction. However, to gain quantitative information of the interactions, the results 
generated with molecular docking need to be further processed with different scoring 
methods to tell the tightness of ligand-protein binding and how well the ligand actually 
binds to its receptor (Sousa et al 2006). Nevertheless, the results obtained with molecular 
docking have been applied with success in virtual screening of large compound databases 
in search for high affinity substrates, prioritizing the hits discovered and in identifying 
substrates with selectivity towards a specified target protein (de Graaf et al 2006). 
 
 
Figure 6: Organization chart representing automated docking algorithms and methods 
and software applied within each approach (Höltje et al 2003, Sousa et al 2006). 
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4.2   Binding affinity predictions 
 
The docking protocol can be considered as a combination of search algorithms for 
energetically favorable conformations and scoring functions of the obtained results (Sousa 
et al 2006). The tightness of ligand-protein interactions is considered by estimating the free 
energy of binding of a ligand on the 3D structure of ligand protein complex (Höltje et al 
2003). In other words, the binding affinity predictions are made based on ligand 
conformations generated with preceding molecular docking. The free energy of binding is 
estimated based on Gibbs-Helmholz equation (Eq. 3) which can be further related to 
binding constant Ki with Eq. 4 (Dill and Bronberg 2003, Höltje et al 2003). 
 
∆G =∆H-T∆S     Eq. 3 
∆G= - RT ln Ki     Eq.4 
ΔH: enthalpy  T: temperature (in Kelvin) ΔS: entropy  Ki: binding constant R: gas constant 
 
The free energy estimations can be conducted using different scoring functions which 
identify a correct binding mode for ligand-protein complex based on lowest energy value 
and rank the docking results according to the binding affinity of ligands (Krovat et al 
2005). In other words, scoring functions complement docking algorithms by evaluating the 
interaction between ligands and target protein (Kitchen et al 2004). In drug development 
process, situations where ΔG < 0 are desired, since in these situations the ligand prefers to 
be bound to the protein and the previously mentioned cascade events leading to response 
can occur (Shimada 2006).  
 
The scoring functions are divided into three categories; force-field based scoring functions, 
empirical scoring functions and knowledge-based scoring functions, respectively (Höltje et 
al 2003, Kitchen et al 2004, Krovat 2005) (Table 7). Also the scoring functions differ in 
accuracy and speed following from approximations being done when predicting binding 
modes and ranking the results (Kitchen et2004, Sousa et al 2006). The overall comparison 
of scoring functions is difficult and it is not possible to generate universal scoring function 
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which could be applied in every occasion with successful results (Krovat 2005, Warren 
2006). Following from this, the lack of congruence indicates the need for improvement of 
scoring functions. Different approaches have been developed to overcome the problems of 
scoring functions, one of which is the use of consensus scoring (Table 7) (Charifson 1999). 
Consensus scoring combines several scoring functions giving higher ranks to binding 
modes placed at the top of the results in all of the scoring function (Krovat 2005). 
Consensus scoring allows detecting false positives more accurately than with single 
scoring function. However, the consensus approach only presents average values, which 
prevent it from outperforming the best scoring function.  
 
The most accurate method to calculate binding constants and free energy of binding for 
ligand-protein complexes is to use free energy perturbation (FEP) calculations which make 
fewer approximations compared to other scoring functions when calculating free energy of 
binding (Knegtel and Grootenhuis 1998). FEP calculations are a part of force-field based 
scoring functions and can be used in determining free energy differences between two 
states. However, FEP calculations are more complex and computationally more demanding 
as well as more time-consuming compared to traditional scoring functions since before 
calculating binding constant for a complex system, several molecular dynamics 
simulations are needed. Also, FEP calculations are suitable only to a narrow range of 
chemical diversity, in other words, for compounds with little or moderate charge and 
flexibility. Consequently, the method is difficult to be applied in most occasions 
considering cytochrome P450s since the substrates of CYPs are known to be relatively 
charged and/or flexible in nature (de Graaf et al 2005a). 
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Table 7: Different scoring functions applied in molecular docking (Höltje et al 2003, 
Kitchen et al 2004, Sousa et al 2006) 
 
Category 
 
Description 
 
Examples 
Force Field-Based Scoring 
Functions 
The sum of interaction energy 
between ligand and receptor and 
internal energy of the ligand is 
quantified. Energy is accounted 
through non-bonded van der 
Waals and electrostatic energy 
terms based on classical 
molecular mechanics force field. 
D-Score, G-Score, GoldScore, 
AutoDock 3.0 Scoring Function 
Empirical Scoring Functions Binding energy is approximated 
by a sum of several individual, 
uncorrelated terms describing 
polar and apolar interactions, 
entropy and desolvation effects. 
Böhm's scoring functions, F-
Score, ChemScore. SCORE, 
Fresno, X-Score 
Knowledge-Based Scoring 
Functions 
Statistically derived rules and 
principles aim to reproduce 
experimentally determined 
structures by using a potential of 
mean force which converts 
structural information into 
Helmholz free interaction 
energies of protein-ligand atom 
pairs.  
Muegges's Potential of Mean 
Force (PMF), DrugScore, SmoG 
score 
Consensus Scoring Information gained from several 
scoring functions is combined to 
get more reliable results and to 
compensate the errors from each 
scoring function 
X-CSCORE (PMF, ChemScore, 
FlexX) 
 
4.3   Molecular dynamics simulations 
 
Molecular dynamics (MD) simulations represent an approach in which protein flexibility 
can be taken into account when considering ligand-protein interactions. Also other 
methods, such as MC methods, rotamer libraries, protein ensemble grids and soft-receptor 
modeling take protein flexibility into account to some extent (Kitchen et al 2004, Sousa et 
al 2006). Although MD simulations can be considered as an integral part of fully flexible 
docking procedures, the simulation methods differ greatly from molecular docking in basic 
principles. MD simulations are based on molecular mechanics and determining 
energetically most favorable 3D structure of a system is derived from Newton's equations 
concerning motion (Eq. 5) (Höltje et al 2003). As such, proteins are handled as a series of 
structures in different conformational states in equilibrium and energetically favorable 
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conformations are systematically searched from the potential energy surface. The 
advantage of MD simulations in exploring ligand-protein interactions is to describe the 
interactions occurring in a molecular system both in time and in space.  
 
Fi (t) = mi  a i( t)     Eq. 5 
Fi: force of atom i at time t mi: mass of the atom ai: acceleration of atom i at time t 
 
With MD simulations also the structural flexibility of the ligand can be taken into account 
as well as water molecules mediating interactions between cytochrome P450s and their 
substrates (de Graaf et al 2005a). Consequently, extremely detailed information of the 
behaviour of ligand-protein complexes at an atomic level is produced and as such, MD 
simulation can be considered the most powerful method describing protein flexibility in 
general (Rueda et al 2007).  
 
MD simulations have been used in several occasions when ligand-protein interactions have 
been examined. The method has been used in the optimization and validation of homology 
models of CYP1A2 (Belkina et al 1998), CYP2B6 (Bathelt et al 2002), 2C9 (Payne et al 
1999b) and 2D6 (Venhorst et al 2003) and in the prediction of catalytic sites for 
cytochrome P450 substrates. Also the behaviour of ligand-protein complex with respect to 
substrate entering or leaving the active site via access of exit channels have been studied 
using molecular dynamics simulations (Wade et al 2004, Cojocaru et al 2007). 
 
Although MD simulations are very powerful tools in exploring ligand-protein interactions, 
the method has some drawbacks. The disadvantage of MD simulations is their dependence 
of the quality of empirically determined force field parameters since atoms in a molecule 
are assumed to be interacting with each other according to force field based rules. Another 
drawback with MD simulations is the huge increase in demand for computer capacity (de 
Graaf et al 2005a, Sousa et al 2006). As such, MD simulations are not – at least not yet – 
applicable to be used systematically when considering ligand-protein interactions in the 
field of modern drug research and discovery. 
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II EXPERIMENTAL PART:                                                                                          
Molecular docking and Comparative Molecular Field Analysis of CYP2B6 Substrates
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1   INTRODUCTION 
 
1.1   CYP2B6 
 
CYP2 family of the cytochrome P450 enzymes catalyzes over 50 % of all the oxidation 
reactions concerning metabolism phase I (Lewis 2003). Approximately 3 % of all the 
known pharmaceutical agents are being metabolized by cytochrome 2B6 (CYP2B6) 
(Bathelt et al 2002, Wang and Halpert 2002). There are several known substrates of the 
isoform and the metabolic pathways of the compounds are versatile. Some of these 
compounds and their chemical reactions catalyzed by cytochromes are represented in 
Table 1. Hydroxylation, demethylation and deethylation can be considered the most 
common reactions catalyzed by CYP2B6. 
 
CYP2B6 is known to activate prodrugs such as anticancer drug cyclophosphamide and also 
procarsinogens such as NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone), which is a 
metabolite of nicotine, and aflatoxin B1 (Code et al 1997). Recently, it has also been 
suggested the isoform participating in substantial amounts in the metabolism of different 
environmental chemicals e.g. insecticides, herbicides and industrial chemicals as well as 
abused toxicants e.g., MDMA and "Ecstasy" (Hodgson and Rose 2006). Due to CYP2B6 
contributing in diverse aspects of biotransformation, it can be considered as a very 
important part of the xenobiotics metabolizing system, although the CYP2B6 percentage of 
the total hepatic content is relatively small when compared to other cytochrome P450 
enzymes. The total hepatic content of CYP2B6 is in most cases estimated to be <1 %, but 
different information can be found in the literature ranging from 0.2 % to 6 % (Ekins et al 
1999b, Turpeinen et al 2004). Accordingly, the amount of CYP2B6 is determined to exist 
in greater amounts than previously thought and as a consequence, the ability of CYP2B6 to 
metabolize drugs and other xenobiotics may well be underestimated. 
 
CYP2B6 is inducible and polymorphic, which leads up to the isoform representing 
significant interindividual differences in CYP2B6 activity. The differences can be 100-fold 
between ethnic groups and gender, and are probably occurring due to variability in the 
hepatic levels of CYP2B6 mRNA and protein. The polymorphism defects in metabolism 
lowering the metabolic clearance of drug substrates, which can be seen with e.g., efavirenz 
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(an inhibitor or HIV-1 reverse transcriptase), ifosfamide and cyclophosphamide, thus 
causing unwanted side effects and potential drug-drug interactions, when co-administered 
with other substrates metabolized via CYP2B6 (Bathelt et al 2002, Lamba et al 2003, Ward 
et al 2003). 
 
Table 1: Known substrates of CYP2B6 and their metabolic pathways.  
 
Substrate  
 
Metabolic pathway 
 
Reference  
S-mephenytoin N-demethylation  Heyn et al 1996 
Diazepam N-demethylation  Ono et al 1996 
7-ethoxy-4-
trifluoromethylcoumarin 
O-deethylation Code et al 1997 
Imipramine N-demethylation  Koyama et al 1997 
RP73401  Ring hydroxylation Stevens et al 1997 
Cyclophosphamide (CPA)  4-hydroxylation Bathelt et al 2002 
Ifosfamide (IFA)  N-deethylation Bathelt et al 2002 
Benzphetamine N-demethylation  Ekins et al 1998 
4-chloromethyl-7-
ethoxycoumarin 
O-deethylation Ekins et al 1998 
3-cyano-7-ethoxycoumarin O-deethylation  Ekins et al 1998 
Midazolam 1'-hydroxylation  Ekins et al 1998 
Antipyrine 4-hydroxylation Ekins et al 1999b 
Cinnarizine p-hydroxylation  Ekins et al 1999b 
7-ethoxycoumarin O-deethylation  Shimada et al 1999 
Testosterone  16β-hydroxylation Hanna et al 2000 
MDMA "Ecstasy" N-dealkylation,  demethylenation Kreth et al 2000 
Propofol  4-hydroxylation Court et al 2001 
Amitriptyline N-demethylation Wang and Halpert 2002 
β-artheether N-demethylation Wang and Halpert 2002 
Benzyloxyresorufin O-debenzylation Wang and Halpert 2002 
Dextrometorphan N-demethylation  Wang and Halpert 2002 
Efavirenz 8-hydroxylation Ward et al 2003 
7-methoxy-4-
trifluoromethylcoumarin 
O-demethylation  Donato et al 2004 
Nicotine N-demethylation  Yamanaka et al 2005 
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1.2 The object of the experimental part 
 
The aim of the study was to explore if the homology model of CYP2B6 (Figure 1) could 
be successfully used in molecular docking of a set of 49 structurally diverse compounds, 
and if it was be possible to create a functional CoMFA model for the compounds by 
correlating their structural properties with experimentally defined inhibition potencies. A 
successful CoMFA model could be further used in virtual screening of large databases in 
combination with other computational approaches, to predict potential CYP2B6 substrates 
and their activities as well as interactions with the protein when combined with 
information derived based on the homology model of CYP2B6. 
 
 
Figure 1: The homology model of CYP2B.
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2   MATERIALS AND METHODS 
 
All computations were performed on a 3,6 GHz Intel Xeon personal computer running 
SuSe Linux 10.1. The inhibition potencies (IC50 values) of structurally diverse compounds 
were determined with recombinant human CYP2B6 enzyme, 7-ethoxy-4-
trifluoromethylcoumarin O-deethylation as a probe reaction. Measurements were 
conducted at the Department of Pharmacology and Toxicology in University of Kuopio. A 
more detailed description of the biochemical assay can be found in an article by Korhonen 
et al 2007.  
 
2.1   Protein setup 
 
The homology model of CYP2B6 has been modeled by Bathelt et al (2002), using X-ray 
structure of CYP2B5 as template with PDB code IDT6 (Brookhaven Protein Data Bank). 
In this research, the homology model was supplemented by adding O2 at the active site, 
above heme iron with a distance from iron atom and oxygen atom closer to the heme iron 
being 1.85 Å and the approximate torsion angels between O – Fe – N1-4 (four nitrogen 
atoms of heme template) adjusted into 95º, 92.85º, 95.38º and 94.96º, respectively. O2 was 
modeled with molecular modeling software using SYBYL 7.1 and sketch approach (Tripos 
Inc). O2 was added into the homology model to prevent the ligands from complex binding 
with the heme iron when docked in the active site. The CYP2B6 protein structure was 
prepared using Sybyl 7.1 by adding hydrogens to the protein structure, and removing 34 
lone electron pairs from the structure before docking with GOLD 3.0. 
 
The solvent-accessible surface of the active site was calculated with FastConnolly method 
in MOLCAD to aid in visual inspection of the active site and the position of substrates in it 
after molecular dockings. 
 
2.2   Ligand setup 
 
Ligands used in molecular docking are represented in Tables 2 and 3. 16 known substrates 
of CYP2B6, which were used in the preliminary dockings, were selected from literature 
(Table 2). The known substrates were used as references in evaluating the degree of 
73 
 
success of molecular docking of the database of 49 ligands (Table 3) into the homology 
model by comparing them to the conformations of the known substrates. All the molecules 
were minimized with Tripos Force Field and partial atomic charges were calculated with 
Gasteiger-Hückel method using default settings in SYBYL 7.1. The 49 compounds and 
their inhibition potencies in vitro are taken from previous studies conducted in University 
of Kuopio concerning CYP2A6, CYP2B6 and CYP1A2 (Rahnasto et al 2005, Korhonen et 
al 2005, Korhonen et al 2007). 
 
The 49 ligands can be divided according to their structure into lactones, aromatic 
molecules, pyridine derivatives and diphenylmethane derivatives. The aromatic 
compounds can be further divided into polyaromatic compounds and derivatives 
containing only one aromatic ring. The inhibitory potencies of the compounds range from 
nanomolar to micromolar, ticlodipine being the most potent and ε- capronolactone the 
weakest inhibitor. 
 
Table 2:The set of 16 known substrates of CYP2B6 used in the preliminary dockings and 
their metabolic pathways.  
 
Substrate  
 
Metabolic pathway 
 
Reference  
S-mephenytoin N-demethylation  Heyn et al 1996 
Diazepam N-demethylation  Ono et al 1996 
7-ethoxy-4-
trifluoromethylcoumarin 
O-deethylation Code et al 1997 
Imipramine N-demethylation  Koyama et al 1997 
RP73401  Ring hydroxylation Stevens et al 1997 
Benzphetamine N-demethylation  Ekins et al 1998 
4-chloromethyl-7-
ethoxycoumarin 
O-deethylation Ekins et al 1998 
3-cyano-7-ethoxycoumarin O-deethylation  Ekins et al 1998 
Midazolam 1'-hydroxylation  Ekins et al 1998 
Antipyrine 4-hydroxylation Ekins et al 1999b 
Cinnarizine p-hydroxylation  Ekins et al 1999b 
7-ethoxycoumarin O-deethylation  Shimada et al 1999 
Testosterone  16β-hydroxylation Hanna et al 2000 
Dextrometorphan  N-demethylation  Wang and Halpert 2002 
7-methoxy-4-
trifluoromethylcoumarin 
O-demethylation  Donato et al 2004 
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2.3   Docking 
 
The compounds were docked using two commercially available molecular docking 
programs, FlexX 1.13.5 L (BioSolveIT) and GOLD 3.0 (The Cambridge Crystallographic 
Data Centre). With FlexX, the CYP2B6 homology model was complemented with bound 
reference structure (7-EFC), and the ligand was checked and modified concerning ligand 
atoms and bond types. The active site was customized by defining the active site first 
within 6.5 Å from the reference structure. In later dockings, the active site range from the 
reference structure was redefined into 8.0 Å and 11.6 Å, respectively. Four ligands, namely 
coumarin, 7-ethoxyresorufin, 7-EFC and 7-MFC (7-methoxy-4-trifluoromethylcoumarin) 
were used in the preliminary dockings using FlexX default settings except maximum 
protein ligand overlap, which was increased into 5, 20 and 100, respectively. The filtering 
of the generated conformations was performed by ranking the affinity of compounds bound 
to the protein with Consensus Scoring (CScore) (Charifson et al 1999). 
 
GOLD dockings were performed using the default settings, and the program was instructed 
to terminate the docking if the best three solutions for each ligand were within 1.5 Å rmsd 
of each other. The ligand binding site was specified to be within 15 Å range of a central 
atom C2205 [Thr 272]. GoldScore was determined as a primary scoring function (Verdonk 
et al 2003), but additional scoring functions were calculated with CScore and X-SCORE 
(Wang et al 2002). 
 
2.4   Comparative molecular field analysis (CoMFA) 
 
23 ligands with IC50 spanning around three log units listed in Table 3 (marked with an 
asterisk) were analyzed using the CoMFA method (Tripos Inc.). The predictive power of 
the model was evaluated by estimating the pIC50 values for 26 ligands not included in the 
preliminary CoMFA model (Table 4). The inhibition potencies of the ligands were 
transformed from IC50 into pIC50; the reverse logarithmic representation of IC50. Partial 
atomic charges were recalculated with MMFF94 method using default settings of SYBYL 
7.1, since a successful CoMFA model could not be generated with Gasteiger-Hückel 
charges regardless of iterative efforts. 
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CoMFA analysis was performed with standard parameters by measuring steric (Lennard-
Jones potential) and electrostatic (Coulomb potential) energies for each molecule by sp
3
 
carbon atom with +1 charge and grid spacing of 2 Å. Column filtering was set to 2 
kcal/mol. The optimum number of components (2) for the non-cross-validated analyses 
was evaluated by leave-one-out (LOO) cross-validation, according to the 5 % rule; if 
adding a component decreased standard error of prediction, smaller number of components 
was chosen. The model was validated using cross-validation for statistical analyses. 
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Table 3: Inhibition potencies (Ic50) and structures of compounds used in molecular 
docking of ligands in the homology model of CYP2B6  
 
Compound 
 IC50 value 
(µM) 
95 % confidence 
intervals 
Ticlodipine 
N
Cl S  
0.09506 0.06919-0.1209 
4-(4-chlorobenzyl)pyridine 
N
Cl  
0.2766 0.1570-0.3962 
4-benzylpyridine 
N
 
0.4141 0.2774-0.5509 
4-(4-nitrobenzyl)pyridine 
N
NO
2  
0.4449 0.3553-0.5345 
4-(4-chlorobenzoyl)pyridine 
N
O
Cl  
1.479 1.201- 1.758 
Selegiline* CH3
N
CH
3
CH
 
3.920 3.385-4.455 
2-benzylaniline* NH2
 
4.431 2.704-6.158 
4-hydroxydiphenylmethane* 
OH  
4.993 2.528-7.457 
4-benzoylpyridine 
N
O
 
5.150 3.802-6.498 
1-naphthol OH
 
9.113 6.605-11.62 
4.4-DDM* 
NH
2
NH
2  
6.834 3.886-9.782 
ThioTEPA 
N P N
N
S
 
10.36 8.220-12.50 
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Table 3 continues    
 
Compound 
 IC50 value 
(µM) 
95 % confidence 
intervals 
4-chlorobenzophenone* O
Cl  
12.53 8.319-16.73 
Piperonylalcohol 
O
O
OH
 
19.80 16.57-23.04 
γ-dodecanolactone* 
O O 
22.19 13.54-30.84 
Bupropion* 
N
H
Cl
O
 
28.13 10.12-46.13 
Undecanoic-γ-lactone* 
O O 
35.31 26.92-43.69 
4-chlorobenzylamine 
Cl
NH
2
 
36.69 26.64-46.74 
4-methoxybenzaldehyde 
O
O
 
36.93 26.98-46.87 
2-methoxynaphthalene* O
 
37.08 29.02-45.14 
Bromodiphenylmethane Br
 
38.77 29.02-48.51 
2(p-tolyl)ethylamine* NH2
 
44.62 28.78-60.47 
4-bromo-benzaldehyde 
Br
O
 
49.80 34.21-65.38 
2-naphthol* OH
 
68.66 41.24-96.08 
4-hydroxybenzophenone 
OH
O
 
95.96 66.53-125.4 
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Table 3 continues    
 
Compound 
 IC50 value 
(µM) 
95 % confidence 
intervals 
4-bromobenzylbromide* 
Br
Br
 
106.6 84.64-128.5 
p-
dimethylaminobenzaldehyde* 
H
O
N
 
106.6 84.64-128.5 
 2,4-dimethylquinoline* 
N CH
3
CH
3
 
137.1 94.29-180.0 
alfa-tetralone* O
 
145.3 117.7-172.9 
δ-decanolactone* 
O O  
154.3 132.6-175.9 
Quinaldine 
N CH
3  
311.6 213.4-409.8 
2-indanone* 
O  
347.7 244.2-451.3 
4-hydroxybenzaldehyde OH
O
 
365.5 298.1-432.9 
3-methylisoquinoline* 
N
CH
3
 
391.1 244.2-538.1 
3-methylquinoline* 
N
CH
3
 
415.0 254.7-575.3 
2,7-dimethylquinoline* 
N CH
3
CH
3  
416.2 321.7-510.7 
3,4-dihydroxybenzaldehyde 
 
OH
OH
O
 
438.0 294.8-581.2 
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Table 3 continues    
 
Compound 
 IC50 value 
(µM) 
95 % confidence 
intervals 
2,6-dimethylquinoline 
N CH
3
CH
3
 
483.5 345.7-621.4 
2-(4-aminophenyl)-ethanol* OH
NH
2  
630.6 216.3-1045 
2,3-dihydrobenzofuran 
O  
667.6 329.8-1005 
Butylbenzene 
 
822.6 611.0-1034 
γ-phenyl-γ-butyrolactone 
O O
 
1119 750.7-1487 
2-coumarone* 
O O  
1139 613.4-1665 
Anisalcohol 
OH
O  
1361 1043-1678 
2-benzoxalinone* 
N
H
O O  
1638 879.0-2397 
γ-heptalactone 
O O  
2354 1633-3075 
δ-hexalactone 
O O  
4704 3758-5650 
 γ-caprolactone 
O O  
6430 4891-7969 
ε-caprolactone 
O O  
28134 26079-30189 
*Compounds used in the preliminary CoMFA model
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Table 4: Compounds used in evaluating the predictive capacity of the CoMFA model 
presenting the actual and predicted pIc50 (M) values 
 
Compound 
 Actual 
pIc50 (M) 
Predicted  
pIc50 (M)* 
Residual 
Ticlodipine 
N
Cl S  
7.02 5.72 1.30 
4-(4-chlorobenzyl)pyridine 
N
Cl  
6.56 6.97 0.41 
4-benzylpyridine 
N
 
6.38 6.14 0.25 
4-(4-nitrobenzyl)pyridine 
N
NO
2  
6.35 6.78 0.43 
4-(4-chlorobenzoyl)pyridine 
N
O
Cl  
5.83 5.67 0.16 
4-benzoylpyridine 
N
O
 
5.29 6.06 0.78 
1-naphthol OH
 
5.04 4.34 0.70 
ThioTEPA 
N P N
N
S
 
4.98 4.27 0.71 
Piperonylalcohol 
O
O
OH
 
4.70 3.65 1.05 
4-chlorobenzylamine 
Cl
NH
2
 
4.44 3.70 0.73 
4-methoxybenzaldehyde 
O
O
 
4.43 3.71 0.72 
Bromodiphenylmethane Br
 
4.41 4.43 0.02 
81 
 
Table 4 continues     
 
Compound 
 Actual 
pIc50 (M) 
Predicted  
pIc50 (M)* 
Residual 
4-bromo-benzaldehyde 
Br
O
 
4.30 3.32 0.98 
4-hydroxybenzophenone 
OH
O
 
4.02 4.40 0.38 
quinaldine 
N CH
3  
3.51 3.77 0.26 
4-hydroxybenzaldehyde OH
O
 
3.44 3.56 0.12 
3,4-dihydroxybenzaldehyde 
 
OH
OH
O
 
3.36 3.47 0.12 
2,6-dimethylquinoline 
N CH
3
CH
3
 
3.32 3.25 0.06 
2,3-dihydrobenzofuran 
O  
3.18 3.50 0.33 
Butylbenzene 
 
3.08 4.33 1.25 
Anisalcohol OH
O  
2.87 2.97 0.11 
γ-heptalactone 
O O  
2.63 2.32 0.31 
γ-phenyl-γ-butyrolactone 
O O
 
2.59 3.37 0.78 
δ-hexalactone 
O O  
2.33 2.29 0.04 
 γ-caprolactone 
O O  
2.19 2.97 0.78 
ε-caprolactone 
O O  
1.55 2.81 1.26 
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Table 5: Optimum number of components determined for the non-cross-validated 
analyses 
 
Number of components 
 
Standard error of prediction (Spress) 
1 0.584 
2 0.564 
3 0.670 
4 0.728 
5 0.740 
 
Table 6: The sums of extrapolated values for test set ligands. Extrapolated values which 
are smaller than Spress 0.564 for the preliminary CoMFA model indicate the actual pIc50 
value being most likely within ± Spress of the predicted value. 
 
Compound 
 
The sum of extrapolated values 
Ticlodipine 0.248736 
4-(4-chlorobenzyl)pyridine 0.362719 
4-benzylpyridine 0.0407435 
4-(4-nitrobenzyl)pyridine 0.482912 
4-(4-chlorobenzoyl)pyridine 0.0193757 
4-benzoylpyridine* 1.05911 
1-naphthol 0.473842 
ThioTEPA 0.0862455 
Piperonylalcohol -0.39926 
4-chlorobenzylamine 0.132469 
4-methoxybenzaldehyde -0.110152 
Bromodiphenylmethane -0.0327824 
4-bromo-benzaldehyde -0.070504 
4-hydroxybenzophenone -0.2841 
Quinaldine 0.0502355 
4-hydroxybenzaldehyde 0.0465036 
3,4-dihydroxybenzaldehyde -0.0324643 
2,6-dimethylquinoline -0.0185621 
2,3-dihydrobenzofuran -0.00299964 
Butylbenzene 0.0229503 
Anisalcohol -0.211753 
γ-heptalactone 0.0711989 
γ-phenyl-γ-butyrolactone 0.0749135 
δ-hexalactone 0.0511918 
γ-caprolactone 0.101879 
ε-caprolactone -0.228327 
*the CoMFA model extrapolates outside the model; the prediction of pIc50 cannot be considered valid  
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3   RESULTS AND DISCUSSION 
 
3.1   Setting up the molecular docking protocol 
 
With FlexX dockings, surprisingly only coumarin was docked in the active site of CYP2B6 
homology model, and all the other substrates were docked entirely outside of it. Changing 
the active site range from 6.5 Å to 8.0 Å and 11.6 Å did not improve the results 
significantly, nor did changing the maximum protein ligand overlap. The best values for 
maximum protein ligand overlap were determined to be 20 and 100 with visual inspection 
of the docked conformations of ligands in the preliminary dockings. Following from this, 
the database of ligands was docked into the active site using these values. When docking 
the database of ligands into the active site, the range was selected to be 8.0 Å within the 
bound reference structure. Approximately 60 % of ligands were positioned in the active 
site and the rest of the ligands outside of it. As such, the results obtained with FlexX could 
be considered neither encouraging nor consistent.  
 
A possible cause for the unsuccessful docking with FlexX might be the hydrophobicity of 
the active site of CYP2B6. The active site is surrounded by aliphatic residues Ala, Leu, Ile 
and Val and aromatic residues Phe and Thr, which can be considered relatively 
hydrophobic amino acids. Accordingly, between the ligands and protein hydrophobic 
interactions are dominant, which is consistent also with previously generated 
pharmacophore models containing more hydrophobic regions than regions for hydrogen 
bond donors or acceptors (Ekins et al 1999b, Wang and Halpert2002). FlexX search 
algorithm starts with finding hydrogen bonds in the ligand-protein. Subsequently, the 
ligand is placed into the active site. Contrary to hydrogen bonds, which have a strict 
direction, angle and distance, hydrophobic interactions are less oriented in space. 
Following from this, the FlexX docking program might have difficulties in placing the 
ligands inside the active site since electronic interactions (hydrogen bond acceptors and 
donors etc.) are possibly not detected or the hydrogen bonds are found located outside the 
active site.  
 
Since all the ligands in the database were not docked properly in the active site nor were 
the known substrates, the decision to change the docking program from FlexX to GOLD 
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was made. Following from this, more reliable results which would be consistent with 
previous studies concerning the docking of known substrates into the active site of 
CYP2B6 were hoped to be achieved.  
 
In the preliminary GOLD dockings, the set of 16 known substrates were docked in the 
active site of CYP2B6 in order to check the usability of the homology model. Most of the 
substrates were successfully docked inside the active site cavity. The best docking 
solutions for the substrates were visually inspected. Only a few exceptions (midazolam, 
imipramine, cinnarizine, antipyrine and benzyloxyresorufin) among the known substrates 
were discovered, which were located outside active site cavity. The most surprising result 
concerning the outliers was benzyloxyresorufin. Benzyloxyresorufin has been successfully 
used in generating CYP2B6 pharmacophore model and is known to complement the 
pharmacophores (Ekins et al 1999b, Wang and Halpert 2002). It is possible that the 
substrates docked in the periphery of the active site have several possible binding modes 
and the conformation, which ligand adapts when binding in the active site of CYP2B6 is 
energetically less favoured than conformations with lower energy but not preferred for 
metabolism to occur. The complex nature of CYP isoforms in substrate binding is 
discussed in more detail in chapter 2.2.1 of the Literature Review. Following from this, the 
conformation most suitable for metabolism could be excluded from the dockings solutions 
and result in positioning the ligand outside the putative active site of the protein. These 
substrates should be further studied to find explanation for their conformation in the active 
site. 
 
Since upmost all of the known substrates were docked inside the active site cavity in a 
reasonable binding mode with respect to their site of metabolism, the approach to use 
GOLD in molecular docking instead of FlexX was concluded to be useful. One of the 
known substrated, 7-EFC in its docked conformation is represented in Figure 3. As a 
conclusion, the results of the preliminary dockings with known substrates of CYP2B6 were 
considered encouraging and the homology model of CYP2B6 to be reliable in further 
studying of CYP2B6 ligands and their binding in the active site. Based on the successful 
docking of the known substrates, the database of 49 ligands (Table 3) was docked with 
GOLD using the same parameters as in the preliminary GOLD dockings of known 
substrates.  
 
85 
 
3.2   Changes in the active site of the original homology model of CYP2B6 
 
Consequently, all ligands in the database were also docked with previously described 
protocol inside active site cavity with reasonable geometries (Figure 2). More detailed 
viewing of the ligands showed three of the ligands, namely 2-benzoxalinone, anisalcohol 
and 4-hydroxybenzophenone forming hydrogen bonds with residue [Arg404]. Most of the 
ligands were also observed binding in a roughly similar conformation to 7-EFC. Based on 
the conformation of the ligands, they were divided into two groups: ligands orientated in 
the active site similarly to 7-EFC, and ligands orientated in a different position from the 
conformation of 7-EFC. PLS-analysis was performed for both of the groups with cross-
validation, in order to construct a successful CoMFA model. However, PLS-analyses for 
both of the groups gave inadequate results, q
2
 values being less than 0.4 in both cases. q
2 
values less than 0.5 indicate the models having little predictive capacity. As a consequence, 
an alternative way to divide the ligands was presented. Closer visual inspection of the 
ligands orientating in the active site similar to 7-EFC showed the ligands being able to 
position in two possible conformation without complete loss of similarity to the 7-EFC 
binding mode. The para-substituent of aromatic ring structure of the ligands could be seen 
pointing towards the heme or to completely opposite direction. As such, two ligands 
representing both orientations, namely 4-hydroxybenzophenone and 4-(4-
chlorobenzoyl)pyridine, were chosen as reference structures. The skeletons of the 
molecules could be superimposed onto each other the substituents excluded. The hydroxyl 
group of 4-hydroxybenzophenone was pointing towards the heme and the chlorine 
substituent of 4-(4-chlorobenzoyl) pyridine in the opposite direction. PLS-analysis was 
again performed for both of the groups, but the results did not improve from the previous 
PLS-analyses giving q
2
 values less than 0.4, respectively. 
  
Following from the unsuccessful PLS-analyses, the structure of the homology model was 
decided to be redefined. First, the orientation of [Arg404], which formed hydrogen bonds 
with three of the ligands, was modified. Based on literature, [Arg404] stabilizes the 
protoporhyrinring. However, if the residue is engaged into another hydrogen bond with a 
ligand the stabilization will be corrupted. Following from this, [Arg404] was protected 
from hydrogen bonding by rotating the torsion angles of the side chains of residues within 
4 Å range of [Arg404], where [Val337] and [Ile84] were positioned. [Arg404] [Val337] 
was decided to left untouched, but the torsion angles of [Ile84] were changed using Sybyl 
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7.1 Biopolymer approach with Lovell method; χ1 was changed from 163.0 to -177.0 and χ2 
from 174.1 to 66.0).  
 
Second, the position of the oxygen above heme iron was changed by rotating the O-O-
bond 180 º. As a result, oxygen was pointing at opposite direction than at the outset still 
preventing complex binding occurring between the ligands and heme iron. The homology 
model was then minimized, and by docking a set of substrates, which consisted of 7-EFC, 
7-MFC and 7-ethoxycoumarin, into the active site and by checking visually the binding 
mode of the substrates with respect to their site of metabolism, the functionality of the 
homology model was confirmed. Visual inspection also showed the substrates to be 
positioning according to the previous, successful GOLD docking. By docking the database 
of ligands in the active site after confirming the functionality of the homology model, it 
was also confirmed that there were no more hydrogen bonds between the ligands and the 
residue [Arg404] in its modified orientation. However, the pharmacophores from literature 
report a hydrogen bond to be crucial part of ligand-protein interaction, even though the 
particular amino acid in the active site of CYP2B6 has not been identified. Since in the 
current CoMFA model were no possibilities for hydrogen bonding, the current CoMFA 
model was considered insufficient. Therefore, additional changes in the homology model 
of CYP2B6 were decided to be conducted. 
 
GRID analysis performed with H2O as a probe suggested water molecules to be locating 
near residue [Ser180], and to be possibly participating in the hydrogen bonding between 
the ligands and CYP2B6. Consequently, the torsion angle of [Ser180] was rotated by 
changing χ1 from 62.0 to 65.0. After rotating the torsion angles of the residue, 7-EFC was 
docked in the active site, and found to be forming a hydrogen bond with [Ser180]. The 
carbonylic oxygen atom attached to the ring structure of 7-EFC was acting as a hydrogen 
bond acceptor and the hydrogen in [Ser180] hydroxyl group as hydrogen bond donor. 
However, the results are not consistent with pharmacophore models created for CYP2B6 
substrates (Ekins et al 1999b, Wang and Halpert 2002). In the pharmacophore models, the 
oxygen atom of 7-EFCs ring acts as a potential hydrogen bond acceptor when in our 
dockings, the carbonyl oxygen attached to the ring acts as a hydrogen bond acceptor. 
Additionally, there are no potential hydrogen bond donors in the active site of the 
homology model near the 7-EFC ring structure, which also indicates H2O participating in 
forming of hydrogen bonds. Following from this, the GRID analysis performed for 
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CYP2B6 is consistent with literature and supports the findings of water molecules having a 
part in hydrogen bonding between the active site and ligands (Wang and Halpert 2002).  
 
Significantly, docking of the database of ligands showed additional hydrogen bonding 
between CYP2B6 and the database of ligands. Most of the hydrogen bonds were formed 
between residues [Phe176] and/or [Ser180] and the ligands (Figures 4 and 5). A CoMFA 
model was build for those conformations of ligands forming hydrogen bonds with the 
active site of CYP2B6. However, the CoMFA model still did not show the model having 
predictive capacity. As a conclusion, the partial atomic charges of all the ligands were 
recalculated with MMFF94 method since better statistics were achieved in using MMFF94 
charges.   
 
After changing the charges, a preliminary CoMFA model was generated for 23 randomly 
selected ligands of the database (Table 4) to explore the effect of redefined charges on 
generating a CoMFA model. Most of the 23 ligands did not form hydrogen bonds with the 
active site of CYP2B6 in the previous dockings. The CoMFA model represented statistical 
values of good quality with two components giving q
2
 value of 0.564, Spress (standard error 
of prediction) of 0.523, and standard r
2
 value of 0.822 with s (standard error of estimation) 
of 0.345. A plot for the training set actual vs. predicted pIc50 values is represented in 
Figure 7 and Spress with different number of components in Table 5. This model was 
applied to predict the inhibition potency of 26 ligands of the database not included in the 
CoMFA model (Table 4), giving predicted r
2
 value 0.787 with s of 0.712. The percentage 
of extrapolated terms and the sum of extrapolated values was examined for the CoMFA 
model to ensure the extrapolated values did not exceed standard error of prediction (0.564). 
The sum of extrapolated values of the test set ligands did not have larger magnitude than 
Spress despite 4-benzoylpyridine (Table 6). The results proved goodness of fit and indicated 
the model having good predictive capacity.  
 
3.3   Interpretation of the CoMFA contour maps 
 
The CoMFA model predicted IC50 value of bromodiphenylmethane most accurately, the 
residual of actual vs. predicted pIC50 being 0.02. Therefore, bromodiphenylmethane is 
chosen as a template structure in interpreting the CoMFA contour maps. The CoMFA 
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model is represented in contour maps in Figure 6 with bromodiphenylmethane as a 
reference structure. 
In the CoMFA map, red colour represents areas where negative charge and hydrogen bond 
acceptors increase the inhibition potency of the ligand, blue represents areas where positive 
charge and hydrogen bond donors decrease the inbition potency of the ligand, green colour 
indicates that steric bulk in these areas increases the inhibition potency, and in yellow 
regions steric bulk decreases the inhibition potency. The CoMFA model is consistent with 
the structure of bromodiphenylmethane; green colour indicates steric bulk being favoured 
near bromide atom between the two benzene rings. Bromide atom has a relatively large 
size and the atom can be considered bulky, which correlates with the green region 
surrounding the atom. As a result, the bromide atom can be considered an important 
contributor in the inhibition potency of the ligand, which is also consistent with the 
information of hydrophobicity being important for the overall inhibitory activity of 
CYP2B6 ligands and complementing the generated pharmacophore models. However, in 
the pharmacophore models several hydrophobic regions in different relative positions were 
found to be important for the activity of ligands, whereas in our CoMFA model only one 
hydrophobic region can be located in the contour map. The CoMFA model also points out 
two strict regions where negative charge and hydrogen bond acceptors would increase the 
inhibition potency of the ligands. The finding is again consistent with the information 
obtained from the pharmacophore models and the structure of CYP2B6 substrates in 
general, since the substrates of CYP2B6 are known to contain one or two hydrogen bond 
acceptors being angular, mostly neutral or basic and rather hydrophobic (Lewis and 
Dickins 2002). However, in the structure of bromodiphenylmethane hydrogen bond 
acceptors do not exist.  
 
The test set of CYP2B6 ligands included also planar molecules whose activity the CoMFA 
model was able to accurately predict. Positive charge and hydrogen bond donors were 
favoured in rather small region in the CoMFA model, and it would be interesting to see the 
effect which fulfilling of these areas according to the CoMFA model would have on the 
inhibition potency of the ligands. Interestingly, not any of the test set ligands possessed 
characteristics complementary to the regions in the contour map favouring positive charge 
and hydrogen bond donors.  
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3.4   Summary 
 
As a summary, the CoMFA model generated was able to predict activities for structurally 
diverse compounds giving statistical values of good quality, and the CoMFA model can be 
considered successful. Nevertheless, it should be beared in mind that despite good 
statistical values and the predictive power of the CoMFA model attained during this 
research, a lot of work is still needed for further improvement and validation of the 
CoMFA model, especially concerning the ligands relating with high residual between the 
actual and predicted IC50, i.e., butylbenzene, ε-caprolactone and ticlodipine. Interestingly, 
ticlodipine is the most potent inhibitor in the test set and it has the greatest difference 
between the actual and predicted inhibition activity. Another CoMFA model for CYP2B6 
ligands with higher predictive capacity has recently been generated in the university of 
Kuopio by Korhonen et al 2007, giving q
2
 value of 0.71, Spress of 0.64 and standard r
2
 value 
of 0.85 with predictive r
2
 being 0.80, proving that high quality CoMFA models for 
structurally diverse CYP2B6 substrates can be put into practice.  
 
With respect to the results obtained from this work, the docking results of the ligands need 
further examination. Although the ligands were positioned in the active site of CYP2B6 
homology model quite analogously, explicit differences could be seen among some of the 
conformations of structurally very similar ligands, possibly affecting the alignment of 
ligands. Successful alignment of the ligands is a key step in generating 3D-QSAR models 
such as CoMFA, and as a consequence, the inconsistent conformations of the structurally 
similar ligands may have hindered the CoMFA model achieving the best possible 
predictive capacity. This leaves questions concerning the seemingly random conformations 
and by definition, the suitability of the particular docking programs (FlexX and GOLD) 
since different docking programs and scoring functions produce different kind of 
information (Warren et al 2006). However, the unsuccessful dockings can be affected by 
the relative hydrophobicity of the active site of CYP2B6. Most of the residues surrounding 
the active site are considered to be hydrophobic and accordingly, do not possess hydrogen 
bond acceptors and donors, which are more distinct for the docking programs to consider 
as crucial contributors to the ligand-protein interactions during ligand binding. It is also 
possible, that using the homology model of CYP2B6 had an effect on the reliability of the 
docking results despite 48 % sequence similarity between isoforms CYP2C5 and CYP2B6. 
Nevertheless, the CYP2B6 homology model has been successfully used in other researches 
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using molecular docking and further research concerning the area is needed before 
conclusions can be made. 
 
In addition, the hydrogen bonds which were formed between residues [Phe176] and/or 
[Ser180] and some of the ligands raise questions. [Phe176] is mentioned in the literature to 
be one of the residues important for substrate metabolism based on mutagenesis studies, 
docking studies and pharmacophore models (Domanski et al 1999, Domanski and Halpert 
2001, Bathelt et al 2002, Wang and Halpert). Significantly, pharmacophore models suggest 
[Phe176] to participate in hydrophobic interactions, whereas in our studies the residue acts 
as hydrogen bond donor. Contrary to [Phe176], there have not been any results in previous 
researches concerning the participation of [Ser180] in ligand binding. Neither the 
mutagenesis studies determining SRS residues nor pharmacophore models with 
information of residues surrounding the regions important to ligand activity have 
pinpointed the possibility of [Ser180] having a role ligand binding. So far, in mutagenesis 
studies only a few particular residues have been shown to participate in ligand binding 
directly or non-directly, namely T292, L363 and F107. As such, this work has pointed the 
possibility of [Ser180] having an important part concerning the interactions between 
CYP2B6 and its ligands, and as such, suggests new features concerning the residues 
important for ligand binding in the active site cavity of the isoform However, whether or 
not the residue really has an effect on ligand binding in the active site of CYP2B6 needs 
further researching. 
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Figure 2: The 49 ligands docked in the active site of CYP2B6. Represented are also the 
fifth ligand, cysteine of the heme template and the two residues, [Phe176],  
[Ser180] which formed hydrogen bonds with the ligands. See text for details. 
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Figure 3:7-EFC positioned in the active site cavity of CYP2B6 with GOLD 3.0 molecular 
docking. Residues surrounding the active site are represented together with the heme 
template. 
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Figure 4:Hydrogen bond between 1-naphtol and 
residue [Ser180]. 
 
 
Figure 5: Hydrogen bonds between 4.4-DDM and 
residues [Phe176] and [Ser180] 
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Figure 6: Color contour map of the CYP2B6 CoMFA model. The reference structure is 
bromodiphenylmethane. Red and green color represents areas where negative charge 
and steric bulk is favored increasing inhibition potency. Blue and yellow color 
represents areas where positive and less bulky groups are favoured, increasing the 
inhibition potency. 
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Figure 7:Plot for training set actual vs. predicted pIc50 values. r
2
 = 0,822 
 
95 
 
4   CONCLUSION 
 
In the experimental part of this work, the homology model of CYP2B6 was evaluated to 
determine if the model could be used in successful docking of structurally diverse 
compounds. Two molecular docking programs which apply different algorithms in 
generating conformations were used, namely FlexX and GOLD. With both programs, a 
series of 16 known substrates of CYP2B6 were preliminary docked in the active site of the 
protein to see if they would be in a position preferred for their metabolism to occur. In this 
research, FlexX did not succeed in docking of the compounds, placing the substrates in the 
periphery of the active site. Contrary, GOLD dockings were successful and majority of the 
known substrates were docked in the active site in a preferred conformation. Respectively, 
all of the 49 ligands in the database were positioned in the active site as expected. Based on 
the successful results of GOLD dockings, a preliminary CoMFA model was generated for 
23 ligands of the database by correlating their structural properties with experimentally 
defined inhibition potencies. The CoMFA model represented statistical values of good 
quality (q
2
 value = 0.523, Spress = 0.564, standard r
2
 = 0.822, s = 0.345). Using the model 
inhibition potencies were successfully predicted for 26 ligands of the database not included 
in the CoMFA model (Table 5), giving predicted r
2
 value 0.787 with s of 0.712. However, 
close visual inspection of the docking results showed differences in the conformations of 
structurally similar ligands, which may have been affecting the predictive power of the 
CoMFA model. Also, ligand-protein interactions are not consistent with previous 
pharmacophore models generated for CYP2B6 substrates or muta-genesis studies 
concerning the suggested SRS´ and residues lining these areas. This too might have an 
effect on the reliability of the generated CoMFA model and its predictive power. As a 
consequence, further studying of the results is needed and although encouraging, at this 
point the results of this research should be viewed critically. 
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